0001104659-21-019846.txt : 20210210 0001104659-21-019846.hdr.sgml : 20210210 20210210163136 ACCESSION NUMBER: 0001104659-21-019846 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210210 DATE AS OF CHANGE: 20210210 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rezolute, Inc. CENTRAL INDEX KEY: 0001509261 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273440894 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39683 FILM NUMBER: 21614341 BUSINESS ADDRESS: STREET 1: 201 REDWOOD SHORES PARKWAY, SUITE 315 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-847-1919 MAIL ADDRESS: STREET 1: 201 REDWOOD SHORES PARKWAY, SUITE 315 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: AntriaBio, Inc. DATE OF NAME CHANGE: 20130114 FORMER COMPANY: FORMER CONFORMED NAME: FITS MY STYLE INC DATE OF NAME CHANGE: 20110104 10-Q 1 tm214780d1_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2020
OR
¨		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 000-54495

REZOLUTE, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	27-3440894
(State of other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

201 Redwood Shores Parkway, Suite 315, Redwood City, California	94065
(Address of Principal Executive Offices)	(Zip Code)

(650) 206-4507

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	RZLT	Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.). x Yes ¨ No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, and an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨	Accelerated filer ¨

Non-accelerated filer x	Smaller reporting company x

	Emerging Growth Company ¨

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 17(a)(2)(B) of the Securities Act. ¨

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ¨ Yes x No

The registrant had 8,352,277 shares of its $0.001 par value common stock outstanding as of February 8, 2021.

	Page

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Unaudited Condensed Consolidated Balance Sheets – December 31, 2020 and June 30, 2020		1

Unaudited Condensed Consolidated Statements of Operations – Three and Six Months Ended December 31, 2020 and 2019		2

Unaudited Condensed Consolidated Statements of Stockholders’ Equity – Six Months Ended December 31, 2020 and 2019		3

Unaudited Condensed Consolidated Statements of Cash Flows – Six Months Ended December 31, 2020 and 2019		4

Notes to Unaudited Condensed Consolidated Financial Statements		5

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		16
Item 3. Quantitative and Qualitative Disclosures About Market Risk		26
Item 4. Controls and Procedures		26

PART II – OTHER INFORMATION

Item 1. Legal Proceedings		27
Item 1A. Risk Factors		27
Item 2. Unregistered Sales of Equity Securities and Use Of Proceeds		28
Item 3. Defaults Upon Senior Securities		28
Item 4. Mine Safety Disclosures		28
Item 5. Other Information		29
Item 6. Exhibits		29

Signatures		30

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (“Report”) contains statements reflecting assumptions, expectations, projections, intentions or beliefs about future events that are intended as “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included or incorporated by reference in this Report, other than statements of historical fact, that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements appear in a number of places, including, but not limited to “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements represent our reasonable judgment of the future based on various factors and using numerous assumptions and are subject to known and unknown risks, uncertainties and other factors that could cause our actual results and financial position to differ materially from those contemplated by the statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts, and use words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “may,” “should,” “plan,” “project” and other words of similar meaning. In particular, these include, but are not limited to, statements relating to the following:

projected operating or financial results, including anticipated cash flows used in operations;

expectations regarding capital expenditures, research and development expense and other payments;

our expectation that the disruptive impact of the COVID-19 pandemic (“COVID-19”) on our business;

our beliefs and assumptions relating to our liquidity position, including our ability to obtain additional financing;

our ability to obtain regulatory approvals for our pharmaceutical drugs and diagnostics; and

our future dependence on third party manufacturers or strategic partners to manufacture any of our pharmaceutical drugs and diagnostics that receive regulatory approval, and our ability to identify strategic partners and enter into license, co-development, collaboration or similar arrangements.

Any or all of our forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks, uncertainties and other factors including, but not limited to, the risks described in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended June 30, 2020 (the “2020 Form 10-K”), filed with the Securities and Exchange Commission (“SEC”) on October 13, 2020.

In addition, there may be other factors that could cause our actual results to be materially different from the results referenced in the forward-looking statements, some of which are included elsewhere in this Report, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Many of these factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. Our actual future results may vary materially from those expressed or implied in any forward-looking statements. All forward-looking statements contained in this Report are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are made, and we disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date of this Report, except as otherwise required by applicable law.

Special Note About COVID-19

We have been actively monitoring the COVID-19 situation and its impact. Our primary objectives have remained the same throughout the pandemic: to support the safety of our team members and their families and continue to support our preclinical studies and clinical trials. While our financial results for the three and six months ended December 31, 2020 and the fiscal year ended June 30, 2020 were not significantly impacted by COVID-19, we cannot predict the impact of the progression of the COVID-19 pandemic on future results due to a variety of factors, including the continued good health of our employees, the ability of us to maintain operations, access to healthcare facilities and patient willingness to participate in our clinical trials, any further government and/or public actions taken in response to the pandemic and ultimately the length of the pandemic. The ultimate impact of the COVID-19 pandemic on our business operations, our ability to raise capital, as well as our preclinical studies and clinical trials remains uncertain and subject to change and will depend on future developments, which cannot be accurately predicted. Any prolonged material disruption of our employees, suppliers, or manufacturing may negatively impact our consolidated financial position, results of operations and cash flows. We will continue to monitor the situation closely.

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

Rezolute, Inc.

Unaudited Condensed Consolidated Balance Sheets (in thousands, except per share amounts)

	December 31,			June 30,
	2020			2020
Assets

Current assets:
Cash and cash equivalents	$	37,600		$	9,955
Prepaid expenses and other		554			563
Total current assets		38,154			10,518

Long-term assets:
Right-of-use assets, net		547			383
Deferred offering costs		122			-
Property and equipment, net		36			33
Lease security deposits		43			31
Total assets	$	38,902		$	10,965

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	612		$	893
Accrued liabilities:
Compensation and benefits		1,264			120
Insurance premiums		-			188
Other		543			180
Current portion of license fees payable to Xoma		-			1,600
Current portion of operating lease liabilities		316			245
Total current liabilities		2,735			3,226

Long-term liabilities:
Operating lease liabilities, net of current portion		281			165
License fees payable to Xoma, net of current portion		-			209
Total liabilities		3,016			3,600

Commitments and contingencies (Notes 4 and 7)

Stockholders' equity:
Preferred Stock, $0.001 par value; 20,000 shares authorized, no shares issued and outstanding		-			-
Common Stock, $0.001 par value, 500,000 shares authorized; 8,352 and 5,867 shares issued and outstanding as of December 31, 2020 and June 30, 2020, respectively		8			6
Additional paid-in capital		193,831			154,595
Accumulated deficit		(157,953	)		(147,236	)
Total stockholders' equity		35,886			7,365
Total liabilities and stockholders' equity	$	38,902		$	10,965

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Rezolute, Inc.

Unaudited Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2020			2019			2020			2019
Operating expenses:
Research and development:
Compensation and benefits, net of related party reimbursements	$	2,124		$	1,750		$	3,336		$	3,168
Clinical trial costs		1,023			1,922			1,781			2,913
Licensing costs		1,000			-			1,000			-
Consultants and outside services		132			972			274			1,458
Material manufacturing costs		134			254			308			441
Facilities and other		83			140			141			292
Total research and development		4,496			5,038			6,840			8,272
General and administrative:
Compensation and benefits		1,943			981			2,648			2,317
Professional fees		481			273			851			633
Facilities and other		232			428			436			677
Total general and administrative		2,656			1,682			3,935			3,627
Total operating expenses		7,152			6,720			10,775			11,899
Operating loss		(7,152	)		(6,720	)		(10,775	)		(11,899	)

Non-operating income - interest and other		55			54			58			153
Net loss	$	(7,097	)	$	(6,666	)	$	(10,717	)	$	(11,746	)

Net loss per common share - basic and diluted	$	(0.88	)	$	(1.14	)	$	(1.54	)	$	(2.08	)

Weighted average number of common shares outstanding - basic and diluted		8,045			5,866			6,956			5,646

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Rezolute, Inc.

Unaudited Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except per share amounts)

					Additional						Total
	Common Stock				Paid-in			Accumulated			Stockholders'
	Shares		Amount		Capital			Deficit			Equity

Six Months Ended December 31, 2020:
Balances as of June 30, 2020		5,867	$	6	$	154,595		$	(147,236	)	$	7,365
Stock-based compensation		-		-		1,775			-			1,775
Fair value of warrants issued to consultants for services		-		-		6			-			6
Issuance of Units for cash		2,485		2		40,998			-			41,000
Advisory fees and other offering costs		-		-		(3,550	)		-			(3,550	)
Issuance of common stock for services		-		-		7			-			7
Net loss		-		-		-			(10,717	)		(10,717	)
Balances as of December 31, 2020		8,352	$	8	$	193,831		$	(157,953	)	$	35,886

Six Months Ended December 31, 2019:
Balances as of June 30, 2019		4,208	$	4	$	128,651		$	(126,903	)	$	1,752
Stock-based compensation		-		-		2,059			-			2,059
Fair value of warrants issued to consultants for services		-		-		73			-			73
Issuance of common stock for cash:
Related parties at $14.50 per share		1,380		2		19,998			-			20,000
Other investors at $14.50 per share		279		-		4,050			-			4,050
Advisory fees and other offering costs		-		-		(1,500	)		-			(1,500	)
Net loss		-		-		-			(11,746	)		(11,746	)
Balances as of December 31, 2019		5,867	$	6	$	153,331		$	(138,649	)	$	14,688

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Rezolute, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows

(in thousands)

	Six Months Ended
	December 31,
	2020			2019

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(10,717	)	$	(11,746	)
Stock-based compensation expense		1,775			2,059
Depreciation and amortization expense		6			9
Non-cash lease expense		139			136
Fair value of warrants issued for services		6			73
Fair value of shares of Common Stock issued for services		7			-
Changes in operating assets and liabilities:
Decrease (increase) in prepaid expenses and other assets		(2	)		423
Increase (decrease) in accounts payable		(412	)		690
Increase (decrease) in other accrued liabilities		1,193			(164	)
Decrease in license fees payable to Xoma		(1,809	)		(5,891	)
Net Cash Used In Operating Activities		(9,814	)		(14,411	)

CASH FLOWS FROM INVESTING ACTIVITIES		-			-

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of Common Stock:
Related parties		-			20,000
Others		-			4,050
Proceeds from issuance of Units		41,000			-
Payment of commissions and other deferred offering costs		(3,541	)		(1,500	)
Net Cash Provided by Financing Activities		37,459			22,550

Net increase in cash, cash equivalents and restricted cash		27,645			8,139
Cash, cash equivalents and restricted cash at beginning of period		9,955			11,573
Cash, cash equivalents and restricted cash at end of period	$	37,600		$	19,712

CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
Cash and cash equivalents, end of period	$	37,600		$	18,182
Restricted cash, end of period		-			1,530
Total cash, cash equivalents and restricted cash, end of period	$	37,600		$	19,712

SUPPLEMENTARY CASH FLOW INFORMATION:
Cash paid for interest	$	-		$	-
Cash paid for income taxes		-			-
Right-of-use assets acquired in exchange for operating lease liabilities		302			-

SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Furniture and equipment received as inducement under operating lease	$	10		$	-
Payables for deferred offering costs		32			-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Rezolute, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

Note 1 — NATURE OF OPERATIONS AND SUMMARY OF SIGNFICANT ACCOUNTING POLICIES

Nature of Operations

Rezolute, Inc. (the “Company”) is a clinical stage biopharmaceutical company incorporated in Delaware in 2010.

Reverse Stock Split

In August 2019, the Company’s Board of Directors approved a reverse stock split that was subject to stockholder approval at a special meeting that was concluded on October 28, 2019. Stockholders approved the proposal whereby the Board of Directors had the ability at any time on or before October 23, 2020 to execute a reverse stock split and set an exchange ratio between 20 and 100 shares of the Company’s outstanding Common Stock, $0.001 par value per share, into one issued and outstanding share of Common Stock, without any change in the par value per share or the number of shares of Common Stock authorized. On October 7, 2020, the Board of Directors approved a fifty shares into one share reverse stock split of the Company’s $0.001 par value Common Stock (the “Reverse Stock Split”), resulting in the filing with the Delaware Secretary of State of a Certificate of Amendment (the “Amendment”) to the Company’s Articles of Incorporation. The Amendment was effective on October 9, 2020.

In connection with the Reverse Stock Split, proportionate adjustments were made to increase the per share exercise prices and decrease the number of shares of Common Stock issuable upon exercise of stock options and warrants whereby approximately the same aggregate price is required to be paid for such securities upon exercise as had been payable immediately preceding the Reverse Stock Split. In addition, any fractional shares that would otherwise be issued as a result of the Reverse Stock Split were rounded up to the nearest whole share. All references in the accompanying unaudited condensed consolidated financial statements to the number of shares of Common Stock and per share amounts have been retroactively adjusted to give effect to the Reverse Stock Split.

Basis of Presentation

The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the SEC for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.

The condensed consolidated balance sheet as of June 30, 2020, has been derived from the Company’s audited consolidated financial statements. The unaudited interim financial statements should be read in conjunction with the Company’s 2020 Form 10-K, which contains the Company’s audited financial statements and notes thereto, together with the Management’s Discussion and Analysis of Financial Condition and Results of Operations for the year ended fiscal June 30, 2020.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnote disclosures necessary for a comprehensive presentation of financial position, results of operations, and cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the three and six months ended December 31, 2020 are not necessarily indicative of the financial condition and results of operations that may be expected for any future interim period or for the fiscal year ending June 30, 2021.

Reclassifications

Certain amounts in the previously issued comparative interim financial statements for the three and six months ended December 31, 2019 have been reclassified to conform to the current interim financial statement presentation. These reclassifications had no effect on the previously reported net loss, working capital, cash flows and stockholders’ equity.

Consolidation

The Company has three wholly owned subsidiaries consisting of AntriaBio Delaware, Inc., Rezolute (Bio) Ireland Limited, and Rezolute Bio UK, Ltd. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its three wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Rezolute, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and the accompanying notes. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company’s significant accounting estimates include, but are not necessarily limited to, fair value of share-based payments, management’s assessment of going concern, accrued clinical trial liabilities, estimates of the probability and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses. Actual results could differ from those estimates.

Risks and Uncertainties

The Company's operations may be subject to significant risks and uncertainties including financial, operational, regulatory and other risks associated with a clinical stage company, including the potential risk of business failure as discussed further in Note 2, and the future impact of COVID-19 as discussed in Note 7.

Significant Accounting Policies

During the six months ended December 31, 2020, there have been no changes in our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020.

Recent Accounting Pronouncements

Standards Required to be Adopted in Future Years. The following accounting standards are not yet effective; management has not completed its evaluation to determine the impact that adoption of this standard will have on the Company’s consolidated financial statements.

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the guidance on the impairment of financial instruments. This update adds an impairment model (known as the current expected credit losses model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes, as an allowance, its estimate of expected credit losses. In November 2019, ASU 2016-13 was amended by ASU 2019-10, Financial Instruments- Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) whereby the effective date for ASU 2016-13 for smaller reporting companies is now required for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity). ASU 2020-06 reduces the number of accounting models for convertible debt instruments and convertible preferred stock, which results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Additionally, ASU 2020-06 affects the diluted earnings per share calculation for instruments that may be settled in cash or shares and for convertible instruments and requires enhanced disclosures about the terms of convertible instruments and contracts in an entity’s own equity. ASU 2020-06 allows entities to use a modified or full retrospective transition method and is effective for smaller reporting companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years.

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not currently expected to have a material impact on the Company’s financial statements upon adoption.

Rezolute, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

Note 2 — Liquidity

The Company is in the clinical stage and has not yet generated any revenues. For the fiscal year ended June 30, 2020, the Company incurred a net loss of $20.3 million and net cash used in operating activities amounted to $24.2 million. For the six months ended December 31, 2020, the Company incurred a net loss of $10.7 million and net cash used in operating activities amounted to $9.8 million. As of December 31, 2020, the Company had an accumulated deficit of $158.0 million, cash and cash equivalents of $37.6 million and total liabilities of $3.0 million.

As discussed in Note 5, on October 9, 2020 the Company received aggregate gross proceeds of $41.0 million from investors in a private placement from the issuance of units that consisted of approximately 2.5 million shares of Common Stock and warrants for the purchase of approximately 0.8 million shares of Common Stock.

As discussed in Note 7, COVID-19 has resulted in an economic environment that is unfavorable for many businesses to conduct operations and pursue new debt and equity financings. The U.S. economy has been adversely affected by mass quarantines and government mandated stay-in-place orders to halt the spread of the virus. These orders are frequently changing and contain inherent uncertainty relative to their future application, creating considerable uncertainty surrounding the recovery period for the U.S. economy. The long-term effects on the Company are expected to result in higher costs in order to comply with safeguards to protect patients and staff engaged in clinical activities, and extended periods of time may be required to complete clinical trials. The current economic environment and financial market volatility is expected to make it more challenging for the Company to obtain funding for its clinical programs in the future. Even if an economic recovery occurs faster and more robustly than currently expected, there are no assurances that the Company will be able to obtain equity and debt financings that will be necessary to fund ongoing operations after March 31, 2022. In addition, even if these financing sources are available, they may be on terms that are not acceptable to the Company’s Board of Directors and stockholders. Management believes the Company’s existing cash and cash equivalents balance will be adequate to carry out currently planned activities at least through March 31, 2022.

Note 3 — OPERATING LEASES

The carrying value of right-of-use (“ROU”) assets and operating lease liabilities are as follows (in thousands):

	December 31,		June 30,
	2020		2020
Right-of-Use Assets, net	$	547	$	383
Operating Lease Liabilities:
Current	$	316	$	245
Long-term		281		165
Total	$	597	$	410

As of December 31, 2020, the weighted average remaining lease term under operating leases was 2.2 years, and the weighted average discount rate for operating lease liabilities was 7.8%. For the three and six months ended December 31, 2020, cash paid for amounts included in the measurement of operating lease liabilities was $65,000 and $134,000, respectively. For the three and six months ended December 31, 2019, cash paid for amounts included in the measurement of operating lease liabilities amounted was $68,000 and $136,000, respectively. These cash payments were included in the determination of net cash used in operating activities in the condensed consolidated statements of cash flows.

Rezolute, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

On October 28, 2020, the Company entered into an assignment, assumption and amendment of lease agreement for ancillary office space in Bend, Oregon. The leased space consists of approximately 5,000 square feet and provides for average monthly rent of approximately $8,700 through the expiration date in February 2024. The lease provides one option to renew the lease for an additional three years at market rates. The Company determined it was not reasonably assured that this renewal option would be exercised whereby the resulting lease term was estimated at 40 months. Using a discount rate of 6.0%, the Company recognized a ROU asset and corresponding operating lease liability of approximately $0.3 million at inception of the lease.

Future payments under all operating lease agreements as of December 31, 2020 are as follows (in thousands):

Fiscal year ending June 30,
Remainder of fiscal year 2021	$	164
2022		283
2023		117
Thereafter		79
Total lease payments		643
Less imputed interest		(46	)
Present value of operating lease liabilities	$	597

Note 4 — License Agreements

Xoma License Agreement

In December 2017, the Company entered into a license agreement (“License Agreement”) with XOMA Corporation (“Xoma”), through its wholly-owned subsidiary, XOMA (US) LLC, pursuant to which Xoma granted an exclusive global license to the Company to develop and commercialize Xoma 358 (formerly X358, now RZ358) for all indications. In January 2019, the License Agreement was amended. with an updated payment schedule, as well as revising the amount the Company was required to expend on development of RZ358 and related licensed products, and revised provisions with respect to the Company’s diligence efforts in conducting clinical studies.

On March 31, 2020, the parties entered into Amendment No. 3 to the License Agreement to extend the payment schedule for the remaining balance of approximately $2.6 million. The revised payment schedule provided for seven quarterly payments to be paid from March 31, 2020 through September 30, 2021.

As discussed in Note 5, the Company completed a private placement of equity securities for gross proceeds of $41.0 million in October 2020, which resulted in acceleration of the entire obligation. On October 23, 2020, the Company paid the outstanding balance of $1.4 million. As of December 31, 2020, the Company does not have any remaining balance payable under Amendment No. 3 to the License Agreement.

Upon the achievement of certain clinical and regulatory events, the Company will be required to make up to $37.0 million in aggregate milestone payments to Xoma.

In addition to the License Agreement between the Company and Xoma in December 2017, both parties also entered into a stock purchase agreement (“Stock Purchase Agreement”). As of December 31, 2020, Xoma owns approximately 162,000 shares of the Company’s Common Stock. The Stock Purchase Agreement provided Xoma with the right and option to require the Company to use its best efforts to facilitate orderly sales of the shares to a third party or purchase the shares (the “Put Option”). Xoma was permitted to exercise the Put Option for up to a total of 50,000 shares of Common Stock for the calendar year ending December 31, 2020, and up to an additional 50,000 shares thereafter. On November 3, 2020, the Company’s shares of Common Stock were approved for listing on the Nasdaq Capital Market and the Put Option terminated pursuant to the terms of the Stock Purchase Agreement.

Rezolute, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

ActiveSite License Agreement

On August 4, 2017, the Company entered into a Development and License Agreement with ActiveSite Pharmaceuticals, Inc. (“ActiveSite”) pursuant to which the Company acquired the rights to ActiveSite’s Plasma Kallikrein Inhibitor program (“PKI Portfolio”). The Company is initially using the PKI Portfolio to develop an oral PKI therapeutic for diabetic macular edema (RZ402) and may use the PKI Portfolio to develop other therapeutics for different indications. The ActiveSite Development and License Agreement requires various milestone payments up to $46.5 million. The first milestone payment for $1.0 million was due after acceptance of an Initial Drug Application, or IND, filed with the U.S. Food and Drug Administration (“FDA”). The Company is also required to pay royalties equal to 2.0% of any sales of products that use the PKI Portfolio.

On October 28, 2020, the Company submitted an IND to the FDA. On December 3, 2020, the Company received FDA clearance for the IND application filed by the Company. This clearance resulted in the Company owing the first milestone payment of $1.0 million, which was paid in December 2020. There have been no events that would result in any royalty payments owed under the ActiveSite Development and License Agreement to date.

Note 5 — STOCKHOLDERS’ EQUITY

For changes in stockholders’ equity for the six months ended December 31, 2020 and 2019, please refer to the unaudited condensed consolidated statements of stockholders’ equity on page 3. The following table presents changes in stockholders’ equity for the three months ended December 31, 2020 and 2019:

					Additional						Total
	Common Stock				Paid-in			Accumulated			Stockholders'
	Shares		Amount		Capital			Deficit			Equity
Three Months Ended December 31, 2020:
Balances as of September 30, 2020		5,867	$	6	$	155,232		$	(150,856	)	$	4,382
Stock-based compensation		-		-		1,141			-			1,141
Fair value of warrants issued to consultants for services		-		-		3			-			3
Issuance of Units for cash		2,485		2		40,998			-			41,000
Advisory fees and other offering costs		-		-		(3,550	)		-			(3,550	)
Issuance of common stock for services		-		-		7			-			7
Net loss		-		-		-			(7,097	)		(7,097	)
Balances as of December 31, 2020		8,352	$	8	$	193,831		$	(157,953	)	$	35,886

Three Months Ended December 31, 2019:
Balances as of September 30, 2019		5,867	$	6	$	152,595		$	(131,983	)	$	20,618
Stock-based compensation		-		-		665			-			665
Fair value of warrants issued to consultants for services		-		-		71			-			71
Net loss		-		-		-			(6,666	)		(6,666	)
Balances as of December 31, 2019		5,867	$	6	$	153,331		$	(138,649	)	$	14,688

Equity Distribution Agreement

On December 18, 2020, the Company and Oppenheimer & Co. Inc. (the “Agent”) entered into an Equity Distribution Agreement (the “EDA”) that provides for an “at the market offering” for the sale of up to $50.0 million in shares of the Company’s Common Stock (the “Placement Shares”) through the Agent. The Agent is acting as sales agent and is required to use commercially reasonable efforts to sell all of the Placement Shares requested to be sold by the Company, consistent with the Agent’s normal trading and sales practices, on mutually agreed terms between the Agent and the Company. The EDA will terminate when all of the Placement Shares have been sold, or earlier upon the election of either the Company or the Agent.

Rezolute, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

The Company has no obligation to sell any of the Placement Shares under the EDA. The Company intends to use the net proceeds, if any, from amounts sold under the EDA for general corporate purposes, including working capital. Under the terms of the EDA, the Company agreed to pay the Agent a commission equal to 3.0% of the gross sales price of the Placement Shares plus certain expenses incurred by the Agent in connection with the offering. Through December 31, 2020, no shares were sold pursuant to the EDA and no commissions were incurred. As of December 31, 2020, total expenses incurred by the Agent and the Company amounted to an aggregate of $0.1 million and are classified as deferred offering costs in the Company’s unaudited condensed consolidated balance sheet.

Reverse Stock Split

As discussed in Note 1, the Company effected Reverse Stock Split on October 9, 2020. All references in the accompanying consolidated financial statements to the number of shares of Common Stock and per share amounts have been retroactively adjusted to give effect to the Reverse Stock Split.

Fiscal 2021 Financing

On September 15, 2020, the Company entered into financial advisory agreements to undertake a private placement of equity or equity equivalent securities (the “Fiscal 2021 Financing”). Pursuant to the financial advisory agreements, the Company agreed to pay transaction fees to the financial advisors for an aggregate of 6.0% of the gross proceeds plus out-of-pocket expenses. In addition, for any financing completed within 60 days of the closing of the Fiscal 2021 Financing, the financial advisors were entitled to additional transaction fees equal to 6.0% of the gross proceeds. As of December 31, 2020, the advisory agreements were no longer active.

On October 9, 2020, the Company completed the Fiscal 2021 Financing through the sale of units (the “Units”) consisting of (i) approximately 2.5 million shares of Common stock, and (ii) warrants entitling the holders to purchase approximately 0.8 million shares of Common Stock (the “Warrants”). The Warrants are exercisable at $19.50 per share for a period of seven years and may be exercised on a cash or cashless basis at the election of the holders.

The Units were issued for a purchase price of $16.50 per Unit, resulting in gross proceeds of $41.0 million. Pursuant to the financial advisory agreements, the Company paid transaction fees of $2.5 million, and costs for professional fees and other offering costs amounted to approximately $1.1 million. After deducting the financial advisory fees and other offering costs, the estimated net proceeds amounted to approximately $37.5 million. Pursuant to the terms of the Fiscal 2021 Financing, the Company executed the Reverse Stock Split of fifty shares into one share as discussed in Note 1 and agreed to enable trading of its Common Stock on the Nasdaq Capital Market, whereby the Company’s listing application was approved by Nasdaq on November 3, 2020. The Company also entered into a registration rights agreement (“RRA”), pursuant to which the Company agreed to use commercially reasonable efforts to register (i) the shares of Common Stock included in the Units, and (ii) the shares of Common Stock issuable upon exercise of the warrants. The Company successfully registered the units on November 27, 2020.

Fiscal 2020 Private Placement

In connection with a Series AA Preferred Stock financing in January 2019, the Company granted call options to Handok, Inc. and Genexine, Inc. (collectively, “H&G”) whereby upon the earlier of (i) December 31, 2020 and (ii) such date that the Company requested H&G to provide additional financing, each investor was entitled to purchase up to $10.0 million of Common Stock at a purchase price equal to the greater of (i) $14.50 per share or (ii) 75% of the volume weighted average closing price (“VWAP”) of the Company’s Common Stock during the thirty consecutive trading days prior to the date of the notice.

On June 19, 2019, the Company entered into a financial advisory agreement to undertake a private placement (the “Fiscal 2020 Private Placement”) of (i) the shares of Common Stock issuable under the H&G call options for a total of $20.0 million, plus (ii) up to $10.0 million of equity or equity equivalent securities to be issued to other investors. On July 23, 2019, the Company entered into purchase agreements whereby H&G exercised their call options to purchase an aggregate of approximately 1.4 million shares of Common Stock for gross cash proceeds of $20.0 million at a purchase price of $14.50 per share. In addition, during July and August 2019 other investors purchased an aggregate of approximately 279,000 shares of Common Stock at a purchase price of $14.50 per share for gross cash proceeds of $4.1 million. Pursuant to the financial advisory agreement, the Company paid a fee of 6.0% of the gross proceeds received from the Fiscal 2020 Private Placement. The total advisory fees and other offering costs amounted to approximately $1.5 million, resulting in net proceeds of $22.6 million for the six months ended December 31, 2019.

Rezolute, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

Restricted Cash

One of the investors in the Fiscal 2020 Private Placement purchased approximately 262,000 shares of Common Stock for gross proceeds of $3.8 million. The Company agreed to spend the proceeds for certain research and development activities and for a planned uplisting of the Company’s Common Stock to the Nasdaq Capital Market. For the three and six months ended December 31, 2019, the Company made qualified expenditures of $1.6 million and $2.3 million, respectively. As of December 31, 2019, the restricted cash balance amounted to $1.5 million. The Company expended the remainder of the restricted cash proceeds on qualified activities by March 31, 2020, whereby there were no restrictions on cash balances after that date.

Note 6 — STOCK-BASED COMPENSATION AND WARRANTS

Stock Option Plans

The Company currently has two active stock option plans consisting of the 2016 Non-Qualified Stock Option Plan, as amended (the “2016 Plan”), and the 2019 Non Qualified Stock Option Plan (the “2019 Plan”). On July 31, 2019, the 2019 Plan was adopted by the Board of Directors and provides authority to grant non-qualified stock options for up to 300,000 shares of the Company’s Common Stock. The Company also has stock options outstanding to purchase up to approximately 43,000 shares of Common Stock under the 2014 Stock and Incentive Plan (the “2014 Plan”) that terminated on March 21, 2019 and approximately 88,000 shares of Common Stock under the 2015 Stock and Incentive Plan (the “2015 Plan”) that terminated on February 23, 2020. Stock options outstanding under the 2014 Plan and the 2015 Plan expire pursuant to their contractual provisions on various dates through 2029. Presented below is a summary as of December 31, 2020 of the number of shares authorized, outstanding, and available for future grants under each of the Company’s stock option plans (in thousands):

	Termination		Number of Shares
Description	Date		Authorized		Outstanding		Available
2014 Plan		March 2019		43		43		-
2015 Plan		February 2020		88		88		-
2016 Plan		October 2021		560		517		43
2019 Plan		July 2029		300		300		-
Total				991		948		43

Stock Options Outstanding

The following table sets forth a summary of the stock option activity for options with time-based vesting and hybrid vesting granted under all of the Company’s stock option plans for the six months ended December 31, 2020 (shares in thousands):

	Shares			Price ⁽¹⁾		Term ⁽²⁾
Outstanding, July 1, 2020		963		$	33.06		8.1
Stock options granted:
Awards with time-based vesting		8			24.05		9.8
Stock options forfeited:
Awards with time-based vesting		(18	)		14.50
Awards with hybrid vesting conditions		(5	)		14.50
Outstanding, December 31, 2020		948			33.43		7.5

Vested, December 31, 2020		514			48.56		6.7

⁽¹⁾

Represents the weighted average exercise price.

⁽²⁾

Represents the weighted average remaining contractual term for the number of years until the stock options expire.

Rezolute, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

Stock-based compensation expense for the three and six months ended December 31, 2020 and 2019 is included in compensation and benefits under the following captions in the unaudited condensed consolidated statements of operations (in thousands):

	Three Months Ended December 31,				Six Months Ended December 31,
	2020		2019		2020		2019
Research and development	$	493	$	351	$	814	$	925
General and administrative		648		314		961		1,134
Total	$	1,141	$	665	$	1,775	$	2,059

Unrecognized stock-based compensation expense related to stock options that provide solely for time-based vesting is approximately $2.2 million as of December 31, 2020. This amount is expected to be recognized over a remaining weighted average period of 1.7 years.

In July 2019, the Company granted employee stock options for approximately 0.2 million shares that commence vesting upon the achievement of market, performance and service conditions (“Hybrid Options”). Total unrecognized compensation cost, net of forfeitures, for the Hybrid Options amounted to approximately $1.9 million as of November 2, 2020. The Hybrid Options will vest ratably over a period of 36 months beginning on the date that all of the following have occurred: (i) the option recipient has been employed by the Company for at least one year, (ii) the Company’s shares of Common Stock have been listed for trading on a national stock exchange, and (iii) such date no later than July 31, 2023, when the Company’s closing stock price exceeds $29.00 per share for 20 trading days in any consecutive 30 day period. On November 3, 2020, the performance condition to obtain a listing on a national stock exchange was achieved, when the Company’s shares began trading on the Nasdaq Capital Market. Prior to this date, no compensation cost had been recognized for the Hybrid Options as it was not considered probable that the performance condition would be achieved. Upon achievement of the performance condition, the Company recognized the cumulative effect of compensation cost of approximately $0.5 million for the period from the grant date through November 3, 2020. The remainder of the unrecognized compensation related to the Hybrid Options of approximately $1.4 million, will be recognized ratably through July 2024 when the Hybrid Options are expected to be fully vested.

Warrants

The Company has issued warrants in conjunction with various debt and equity financings and for services. The following table sets forth a summary of the warrant activity for the six months ended December 31, 2020 (shares in thousands):

	Shares			Price ⁽¹⁾		Term ⁽²⁾
Outstanding, July 1, 2020		618		$	57.46		2.3
Warrants issued		820	⁽³⁾		19.50
Outstanding, December 31, 2020		1,438			35.82		4.6

⁽¹⁾

Represents the weighted average exercise price.

	⁽²⁾	Represents the weighted average remaining contractual term for the number of years until the warrants expire.

⁽³⁾

Represents warrants granted in connection with the October 9, 2020 private placement. The warrants are exercisable for $19.50 per share for a period of 7 years and may be exercised on a cash or cashless basis at the election of the holder.

Rezolute, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

Note 7 — COMMITMENTS AND CONTINGENCIES

Commitments

Please refer to Note 4 for further discussion of commitments to make milestone payments and to pay royalties under license agreements with Xoma and ActiveSite.

COVID-19

In December 2019, COVID-19 was reported to have surfaced in Wuhan, China, and by March 2020 the spread of the virus had resulted in a world-wide pandemic. The U.S. economy has been adversely affected by mass quarantines and government mandated stay-in-place orders to halt the spread of the virus. While these orders are being lifted gradually, a full recovery of the U.S. economy may not occur until 2021 or later. Federal and state governments in the U.S. have approved funding for many programs that may provide financial assistance to individuals and businesses. The Company intends to pursue all material types of government assistance that it may be entitled to. However, no assurance can be provided that the Company will qualify and realize any material benefits from such assistance.

COVID-19 has resulted in an economic environment that is unfavorable for many businesses to pursue new equity financings. Accordingly, the current economic environment is expected to present greater challenges for the Company to obtain additional funding for its clinical programs on terms that are acceptable to the Company’s Board of Directors.

In February 2020, Rezolute announced the initiation of its Phase 2b trial in congenital hyperinsulinism. New site initiation and enrollment resumed in the quarter ended December 31, 2020. However, similar to many other clinical studies conducted by other companies throughout the world, effects of the pandemic remain uncertain, and no guarantees can be made that hold in future site initiation or enrollment will not be encountered again. There are no mitigation strategies we can employ to help avoid potential timeline delays should there be an extended enrollment pause due to COVID-19. The long-term effects of COVID-19 are expected to require additional safeguards to protect patients and staff engaged in clinical activities, and extended periods of time required to complete clinical trials, both of which are expected to result in higher overall costs. While the current business disruption is expected to be temporary, the long-term financial impact and the duration cannot be reasonably estimated at this time.

Legal Matters

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of December 31, 2020, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the Company’s results of operations. At each reporting period, the Company evaluates known claims to determine whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal fees are expensed as incurred.

Note 8 — RELATED PARTY TRANSACTIONS

Related Party Licensing Agreement

On September 15, 2020, the Company entered into an exclusive license agreement with Handok, Inc. (the “Handok License”) for the territory of the Republic of Korea. The Handok License relates to pharmaceutical products in final dosage form containing the pharmaceutical compounds developed or to be developed by the Company, including those related to RZ358 and RZ402. The Handok License is in effect for a period of 20 years after the first commercial sale of each product, and requires (i) milestone payments of $0.5 million upon approval of a New Drug Application (“NDA”) for each product in the territory, and (ii) the Company will sell products ordered by Handok at a transfer price equal to 70% of the net selling price of the products. To date, no milestone payments have been earned by the Company.

Equity Issuances

As discussed in Note 5, on July 23, 2019 Handok, Inc. and Genexine, Inc. agreed to purchase an aggregate of approximately 1.4 million shares of Common Stock at an issuance price of $14.50 per share for gross proceeds of $20.0 million. This purchase was made pursuant to the terms of call options that was issued in connection with an equity offering in January 2019 that resulted in gross proceeds of $25.0 million.

Rezolute, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

On June 26, 2020, Handok entered into a 10b5-1 purchasing plan (the “10b5-1 Plan”) with JMP Securities. Subject to the terms of the 10b5-1 Plan, Handok has purchased on the open market an aggregate of approximately 189,000 shares of our Common Stock through December 31, 2020. As of December 31, 2020, Handok, Inc. owns approximately 24% and Genexine, Inc. owns approximately 22% of the Company’s outstanding shares of Common Stock.

Master Services Agreement

Effective July 1, 2019, the Company entered into a Master Services Agreement (“MSA”) with H&G whereby the Company agreed to assist H&G in an evaluation of their long acting growth hormone program referred to as GX-H9. For the six months ended December 31, 2019, the Company charged H&G for employee services of approximately $103,000 and reimbursable expenses incurred with unrelated parties of approximately $144,000, for a total of approximately $247,000. Amounts charged under the MSA for employee services are reflected as a reduction of research and development compensation costs in the accompanying unaudited condensed consolidated statement of operations for the six months ended December 31, 2019. No related expenses were charged for the three and six months ended December 31, 2020, and for the three months ended December 31, 2019.

Note 9 — INCOME TAXES

Income tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date operating results, plus any significant unusual or infrequently occurring items which are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating results for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known or as the tax environment changes.

For the three and six months ended December 31, 2020 and 2019, the Company did not record any income tax benefit due to a full valuation allowance on its deferred tax assets. The Company did not have any material changes to its conclusions regarding valuation allowances for deferred income tax assets or uncertain tax positions for the three and six months ended December 31, 2020 and 2019.

Note 10 — EARNINGS PER SHARE

Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. For the three and six months ended December 31, 2020 and 2019, basic and diluted net loss per share were the same since all common stock equivalents were anti-dilutive. As of December 31, 2020 and 2019, the following outstanding potential common stock equivalents were excluded from the computation of diluted net loss per share since the impact of inclusion was anti-dilutive (in thousands):

	2020		2019
Stock options		948		960
Warrants		1,438		924
Total		2,386		1,884

Note 11 — FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS

Fair Value Measurements

Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair measurement:

Rezolute, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

Level 1—Quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

Level 2—Other than quoted prices included in Level 1 that are observable for the asset and liability, either directly or indirectly through market corroboration, for substantially the full term of the asset or liability.

Level 3—Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any market activity for the asset or liability at the measurement date.

Due to the relatively short maturity of the respective instruments, the fair value of cash and cash equivalents, accounts payable and accrued liabilities approximated their carrying values as of December 31, 2020 and June 30, 2020. The Company did not have any assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 and June 30, 2020. The Company’s policy is to recognize asset or liability transfers among Level 1, Level 2 and Level 3 as of the actual date of the events or change in circumstances that caused the transfer. During the three and six months ended December 31, 2020 and 2019, the Company did not have any transfers of its assets or liabilities between levels of the fair value hierarchy.

Significant Concentrations

Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash and cash equivalents at high-quality financial institutions. For the six months ended December 31, 2020, cash deposits have exceeded the amount of federal insurance provided on such deposits. As of December 31, 2020 and June 30, 2020, the Company had cash and cash equivalents with a single financial institution with an aggregate balance of $37.6 million and $10.0 million, respectively. The Company has never experienced any losses related to its investments in cash and cash equivalents.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Certain figures, such as interest rates and other percentages included in this section have been rounded for ease of presentation. Percentage figures included in this section have not in all cases been calculated on the basis of such rounded figures but on the basis of such amounts prior to rounding. For this reason, percentage amounts in this section may vary slightly from those obtained by performing the same calculations using the figures in our unaudited condensed consolidated financial statements or in the associated text. Certain other amounts that appear in this section may similarly not sum due to rounding.

Recent Developments

On October 9, 2020, we completed a private placement of equity securities that resulted in net proceeds of approximately $37.5 million. The completion of this private placement triggered the repayment of our obligations to Xoma with a remaining balance due of $1.4 million as of September 30, 2020. Effective October 9, 2020, we implemented a fifty shares into one share Reverse Stock Split of our $0.001 par value Common Stock. On November 3, 2020, we obtained approval from Nasdaq to have our shares of common stock listed on the Nasdaq Capital Market.

In December 2020, the Company entered into an Equity Distribution Agreement (“EDA”), pursuant to which the Company may offer and sell, from time to time, shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering price of up to $50.0 million.

Please refer to our discussion under Liquidity and Capital Resources below and in Notes 1, 2, 4, and 5 to our unaudited condensed consolidated financial statements for further discussion of the private placement, Early Payments due to Xoma, and the Reverse Stock Split.

Special Note About COVID-19

Summary of Clinical Assets

Our lead clinical asset, RZ358, is an antibody therapy in Phase 2b development as a potential treatment for congenital hyperinsulinism ("HI"), an ultra-rare pediatric genetic disorder. In February 2020, we announced the initiation of the RZ358-606 Phase 2b study (“RIZE”) globally at multiple study centers. Prior to COVID-19, we had planned to complete the RIZE study by the middle of calendar year 2021. In March 2020, we paused the RIZE study as a result of the COVID-19 pandemic. As the COVID-19 pandemic abates in different regions, we are resuming clinical activities including trial site initiations and as of January 2021, we have recommenced patient enrollment. Subject to COVID-19 conditions, we believe we will be able to complete the RIZE study in the second half of calendar year 2021.

Our next program, RZ402, is an oral therapy currently in Phase 1 development, targeting diabetic macular edema (“DME”). In October 2020 we submitted an IND to the FDA, which was cleared in December 2020. On January 12, 2021 we dosed the first patient in the Phase 1 clinical trial for RZ402. We expect to complete the study in the first half of the 2021 calendar year.

RZ358

Congenital HI is an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. Congenital HI is caused by mutations in about a dozen known genes associated with pancreatic beta cells and their secretion of insulin. If untreated, it can lead to dangerously low blood sugar levels. Rezolute’s lead candidate, RZ358, is an antibody in Phase 2b development that is designed to prevent severe, persistent low blood sugar in patients with congenital HI.

RZ358 is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor throughout the body, such as in the liver, fat, and muscle. The antibody modifies insulin's binding and signaling to maintain glucose levels in a normal range which counteracts the effects of elevated insulin in the body. Therefore, we believe that RZ358 is ideally suited as a potential therapy for conditions characterized by excessive insulin levels, and it is being developed to treat the hyperinsulinism and low blood sugar characteristic of diseases such as congenital HI. As RZ358 acts downstream from the beta cells, it has the potential to be universally effective at treating congenital HI caused by any of the underlying genetic defects.

The RIZE study is a multi-center, open-label, repeat-dose Phase 2b study of RZ358 in four sequential dosing cohorts of patients with congenital HI who are at least two years old and have residual low blood sugar (<70 mg/dL) that is inadequately controlled on existing therapies. In addition to safety and pharmacokinetic evaluations, continuous glucose monitoring (“CGM”) and self-monitored blood glucose will be utilized to evaluate several glycemic efficacy endpoints. The primary endpoint is the time within a glucose target range of 70-180 mg/dL by CGM during weeks 4 and 8 of treatment compared to baseline.

RZ402

DME is a severe complication of diabetes marked by progressive vision loss and blindness. Consistently high blood sugar levels can cause diabetic retinopathy, a complication characterized by damage to the blood vessels in the eye and fluid leakage into the light-sensitive tissue known as the retina. The accumulation of fluid may lead to DME, or swelling of the macula, the part of the retina responsible for sharp, straight-ahead vision. Currently available treatments for DME involve frequent burdensome injections into the eye or invasive laser surgery.

Rezolute is developing RZ402, a small molecule plasma kallikrein inhibitor (“PKI”) for use in DME. As a once-daily oral investigational therapy, RZ402 is designed to improve compliance and treatment outcomes for patients with DME. Elevated plasma levels of the enzyme kallikrein have been associated with increased inflammation, vessel leakage and excess blood vessel growth in the eyes of patients with DME. Genetic and pharmacologic knockout of plasma kallikrein have been shown to protect against vascular endothelial growth factor (“VEGF”) induced retinal blood vessel leakage in murine models without damaging long-term effects.

RZ402 is a bioavailable small molecule inhibitor of plasma kallikrein that has shown the ability to prevent the onset of and reverse vascular leakage in a dose-dependent manner in multiple rodent models of whole body and retinal vascular leakage. Target plasma concentrations were exceeded for 24 hours following oral dosing of RZ402 in monkeys and dogs, supporting the potential for once daily dosing in humans. We have completed animal toxicology studies and we filed an IND with the FDA on October 28, 2020, which was cleared by the FDA on December 3, 2020 and we initiated a Phase 1 single-dose study in healthy volunteers in January 2021.

Factors Impacting our Results of Operations

We have not generated any revenues since our inception in March 2010. Due to the time required to conduct clinical trials and obtain regulatory approval for any of our product candidates, we anticipate it will be some time before we generate substantial revenues, if ever. We expect to generate operating losses for the foreseeable future; therefore, we expect to continue efforts to raise additional capital to maintain our current operating plans beyond the next year. We cannot assure you that we will secure such financing or that it will be adequate for the long-term execution of our business strategy. Even if we obtain additional financing, it may be costly and may require us to agree to covenants or other provisions that will favor new investors over our existing stockholders.

Key Components of Consolidated Statements of Operations

Research and development expenses. Research and development expenses (“R&D”) consist primarily of compensation and benefits for our personnel engaged in R&D activities, clinical trial costs, licensing costs, and consultants and outside services. Our research and development compensation costs include an allocable portion of our cash and stock-based compensation, employee benefits, and consulting costs related to personnel engaged in the design and development of product candidates and other scientific research projects. We also allocate a portion of our facilities and overhead costs based on the personnel and other resources devoted to R&D activities.

General and administrative expenses. General and administrative expenses (“G&A”) consist primarily of (i) an allocable portion of our cash and stock-based compensation and employee benefits related to personnel engaged in our administrative, finance, accounting, and executive functions, and (ii) an allocable portion of our facilities and overhead costs related to such personnel. G&A expenses also include travel, legal, auditing, consulting, investor relations and other costs primarily related to our status as a public company.

Interest and other income. Interest and other income consist primarily of interest income earned on temporary cash investments.

Critical Accounting Policies and Significant Judgments and Estimates

Overview

The discussion herein is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported revenue and expenses during the reporting periods. These items are monitored and analyzed for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ from these estimates under different assumptions or conditions.

With respect to our significant accounting policies that are described in Note 1 to our consolidated financial statements included in Item 8 of our 2020 Form 10-K, we believe that the following accounting policies involve a greater degree of judgment and complexity. Accordingly, these are the policies we believe are the most critical to aid in fully understanding and evaluating our consolidated financial condition and results of operations.

Research and Development

R&D costs are expensed as incurred. Intangible assets related to in-licensing costs under license agreements with third parties are charged to expense unless we are able to determine that the licensing rights have an alternative future use in other R&D projects or otherwise.

Clinical Trial Accruals

Clinical trial costs are a component of R&D expenses. We accrue and recognize expenses for clinical trial activities performed by third parties based upon estimates of the percentage of work completed over the life of the individual study in accordance with agreements established with clinical research organizations and clinical trial sites. We determine the estimates through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.

Nonrefundable advance payments for goods and services that will be used or rendered in future R&D activities, are deferred and recognized as expense in the period that the related goods are delivered, or services are performed.

Stock-Based Compensation Expense

We measure the fair value of services received in exchange for all stock options granted based on the fair value of the award as of the grant date. We compute the fair value of stock options with time-based vesting using the Black-Scholes-Merton (“BSM”) option-pricing model and recognize the cost of the equity awards over the period that services are provided to earn the award. For awards granted which contain a graded vesting schedule, and the only condition for vesting is a service condition, compensation cost is recognized on a straight-line basis over the requisite service period as if the award was, in substance, a single award. We recognize the impact of forfeitures in the period that the forfeiture occurs, rather than estimating the number of awards that are not expected to vest in accounting for stock-based compensation.

We have granted stock options with vesting that is dependent on achieving certain market, performance and service conditions (“Hybrid Options”). For purposes of recognizing compensation cost, we determine the requisite service period as the longest of the derived, implicit and explicit vesting periods for each of the market, performance and service conditions, respectively. Due to achievement of the performance condition, we began recognizing compensation cost using the grant date fair value in November 2020 and continuing through the end of the requisite service period. Determination of the requisite service period of the Hybrid Options was based on the date that the performance condition was achieved. If the Hybrid Options do not ultimately become exercisable due to the option holders’ failure to achieve the required service period, any previously recognized compensation cost will be reversed.

Results of Operations

Three months ended December 31, 2020 and 2019

Results of operations for the three months ended December 31, 2020 and 2019 reflect net losses of approximately $7.1 million and $6.7 million, respectively. Our unaudited condensed consolidated statements of operations for the three months ended December 31, 2020 and 2019, along with the changes between periods, are presented below (dollars in thousands):

							Changes
	2020			2019			Amount			Percent
Operating expenses:
Research and development:
Compensation and benefits, net of related party reimbursements	$	2,124		$	1,750		$	374			21	%
Clinical trial costs		1,023			1,922			(899	)		-47	%
Licensing costs		1,000			-			1,000			100	%
Consultants and outside services		132			972			(840	)		-86	%
Material manufacturing costs		134			254			(120	)		-47	%
Facilities and other		83			140			(57	)		-41	%
Total research and development		4,496			5,038			(542	)		-11	%

General and administrative:
Compensation and benefits		1,943			981			962			98	%
Professional fees		481			273			208			76	%
Facilities and other		232			428			(196	)		-46	%
Total general and administrative		2,656			1,682			974			58	%
Total operating expenses		7,152			6,720			432			6	%
Operating loss		(7,152	)		(6,720	)		(432	)		6	%
Non-operating income - interest and other		55			54			1			2	%
Net loss	$	(7,097	)	$	(6,666	)	$	(431	)		6	%

Presented below is a discussion of the key factors that resulted in changes in our results of operations for these periods.

Revenue. As a clinical stage company, we did not generate any revenue for the three months ended December 31, 2020 and 2019. We are at an early stage of development as a proprietary product specialty pharmaceutical company and we do not currently have any commercial products. Our existing product candidates will require extensive additional clinical evaluation, regulatory review, significant marketing efforts and substantial investment before they generate any revenues. We do not expect to be able to market any of our product candidates for several years.

Research and development expenses. R&D expenses decreased from approximately $5.0 million for the three months ended December 31, 2019 to approximately $4.5 million for the three months ended December 31, 2020, a decrease of $0.5 million. As a result of the COVID-19 pandemic, we were forced to curtail many of our R&D activities for the three months ended December 31, 2020. Compensation and benefits and licensing costs increased while the remaining categories of our R&D expense decreased for the three months ended December 31, 2020, as discussed below.

For the three months ended December 31, 2020, we had an increase of approximately $0.4 million in compensation and benefits for our R&D workforce, which was attributable to an increase of $0.2 million in stock-based compensation expense and $0.2 million related to cash-based compensation. Stock-based compensation for our R&D workforce increased by $0.2 million primarily due to achievement of the performance condition related to our Nasdaq uplisting that resulted in expense recognition of $0.2 million in November 2020. After November 2020, compensation expense for the Hybrid Options is being recognized ratably over the remaining vesting period. Cash-based compensation increased by $0.2 million for the three months ended December 31, 2020 due to annual performance bonuses earned by members of our R&D workforce.

Clinical trial costs decreased from approximately $1.9 million for the three months ended December 31, 2019 to approximately $1.0 million for the three months ended December 31, 2020. For the three months ended December 31, 2020, we incurred $1.0 million for clinical trial costs that was primarily attributable to $0.7 million related to RZ358, $0.2 million for AB101 and $0.1 million for RZ402. For the three months ended December 31, 20219, clinical trial costs consisted of $1.6 million for the initiation of the Phase 2b clinical program in preparation of patient enrollment for RZ358. For the three months ended December 31, 2019, we also incurred $0.3 million of clinical trial costs for contract research costs in our AB101 first-in-human Phase 1 study for which we received top-line results in December 2019. Upon receipt of the AB101 top line results, we determined that additional formulation adjustments are required before further clinical studies can be undertaken. As a portfolio management decision, we have decided not to take the program further in development and expect that future expenditures related to the program will be insignificant.

Licensing costs increased by $1.0 million for the three months ended December 31, 2020 compared to the three months ended December 31, 2019, which was attributable to the $1.0 million milestone payment due to ActiveSite upon FDA clearance of our RZ402 IND application. In January 2021, we announced the initiation of dosing in a Phase 1 first-in-human clinical study of RZ402. The study (RZ402-101) is a single-center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of RZ402 in healthy adult volunteers. We expect to complete the study in the first half of the 2021 calendar year and anticipates increased clinical trial costs through the end of fiscal year 2021.

Consulting and outside services decreased from approximately $1.0 million for the three months ended December 31, 2019 to approximately $0.1 million for the three months ended December 31, 2020. For the three months ended December 31, 2019, we incurred higher consulting spending of $0.3 million related to RZ358 and $0.7 million for RZ402. For the three months ended December 31, 2020, consulting and outside services of $0.1 million related to RZ358, RZ402 and patent maintenance costs.

Material manufacturing costs decreased from approximately $0.2 million for the three months ended December 31, 2019 to $0.1 million for the three months ended December 31, 2020, a decrease of $0.1 million. The decrease in our material manufacturing costs was primarily due to decreased spending in RZ358 for CMC drug product stability and storage.

Costs allocable to R&D activities for facilities and other costs decreased by approximately $57,000 for the three months ended December 31, 2020 compared to the three months ended December 31, 2019. The decrease was primarily attributable to reduced spending for travel and generally lower overall levels of R&D activity associated with the COVID-19 pandemic for the three months ended December 31, 2020.

As discussed below under the caption Liquidity and Capital Resources, we intend to use the proceeds from our October 2020 financing to advance our clinical programs and fulfill our milestone obligations under the amended License Agreement with Xoma. Accordingly, we currently expect our R&D spending will increase sequentially during calendar 2021 but this could change depending on the ongoing impact of the COVID-19 pandemic.

General and administrative expenses. G&A expenses increased from approximately $1.7 million for the three months ended December 31, 2019 to approximately $2.7 million for the three months ended December 31, 2020, an increase of $1.0 million. This increase was primarily attributable to increases in compensation and benefits for our administrative and executive workforce of $1.0 million.

The increase of $1.0 million in compensation and benefits was primarily attributable to an increase in stock-based compensation expense of $0.3 million and cash-based compensation of $0.6 million. Stock-based compensation for our G&A workforce increased by $0.3 million primarily due to achievement of the performance condition related to our Nasdaq uplisting that resulted in expense recognition of $0.3 million in November 2020. After November 2020, compensation expense related to the Hybrid Options is being recognized ratably over the remaining vesting period. Cash-based compensation increased by $0.6 million for the three months ended December 31, 2020 due to annual performance bonuses earned by members of our G&A workforce.

For the three months ended December 31, 2020, the increase in professional fees of approximately $0.2 million was primarily attributable to increased spending on investor relations connected with the Nasdaq uplisting and related transactions.

Our facilities and other costs decreased by approximately $0.2 million for the three months ended December 31, 2020, primarily due to reduced travel and office-related expenses due to COVID-19 restrictions and a reduction in property tax expense.

Income Taxes. For the three months ended December 31, 2020 and 2019, we did not recognize any income tax benefit due to our net losses and our determination that a full valuation allowance was required for our deferred tax assets.

Six months ended December 31, 2020 and 2019

Results of operations for the six months ended December 31, 2020 and 2019 reflect net losses of approximately $10.7 million and $11.7 million, respectively. Our unaudited condensed consolidated statements of operations for the six months ended December 31, 2020 and 2019, along with the changes between periods, are presented below (dollars in thousands):

							Changes
	2020			2019			Amount			Percent
Operating expenses:
Research and development:
Compensation and benefits, net of related party reimbursements	$	3,336		$	3,168		$	168			5	%
Clinical trial costs		1,781			2,913			(1,132	)		-39	%
Licensing costs		1,000			-			1,000			100	%
Consultants and outside services		274			1,458			(1,184	)		-81	%
Material manufacturing costs		308			441			(133	)		-30	%
Facilities and other		141			292			(151	)		-52	%
Total research and development		6,840			8,272			(1,432	)		-17	%

General and administrative:
Compensation and benefits		2,648			2,317			331			14	%
Professional fees		851			633			218			34	%
Facilities and other		436			677			(241	)		-36	%
Total general and administrative		3,935			3,627			308			8	%
Total operating expenses		10,775			11,899			(1,124	)		-9	%
Operating loss		(10,775	)		(11,899	)		1,124			-9	%
Non-operating income - interest and other		58			153			(95	)		-62	%
Net loss	$	(10,717	)	$	(11,746	)	$	1,029			-9	%

Presented below is a discussion of the key factors that resulted in changes in our results of operations for these periods.

Revenue. As a clinical stage company, we did not generate any revenue for the six months ended December 31, 2020 and 2019. We are at an early stage of development as a proprietary product specialty pharmaceutical company and we do not currently have any commercial products. Our existing product candidates will require extensive additional clinical evaluation, regulatory review, significant marketing efforts and substantial investment before they generate any revenues. We do not expect to be able to market any of our product candidates for several years.

Research and development expenses. R&D expenses decreased from approximately $8.3 million for the six months ended December 31, 2019 to approximately $6.8 million for the six months ended December 31, 2020, a decrease of $1.5 million. As a result of the COVID-19 pandemic, we were forced to curtail many of our R&D activities for the six months ended December 31, 2020. Compensation and benefits and licensing costs increased while the remaining categories of our R&D expense decreased for the six months ended December 31, 2020, as discussed below.

For the six months ended December 31, 2020, we had an increase of approximately $0.2 million in compensation and benefits for our R&D workforce, which was attributable to a $0.3 million increase related to cash-based compensation partially offset by a decrease of $0.1 million in stock-based compensation expense. Cash-based compensation increased by $0.3 million for the six months ended December 31, 2020 primarily due to annual performance bonuses earned by members of our R&D workforce partially offset by the receipt of the CARES Act employee retention credit in September 2020. Stock-based compensation decreased by $0.1 million primarily due to certain stock options that were forfeited or became fully vested by December 2019, resulting in no further compensation expense after that date.

For the six months ended December 31, 2020, we incurred $1.8 million for clinical trial costs primarily related to RZ358. For the six months ended December 31, 2019, we incurred $2.9 million for clinical trial costs that consisted of $2.2 million related to RZ358 and $0.7 million for AB101. Decreased expenditures in the six months ended December 31, 2020 were due to the ongoing COVID-19 pandemic delaying certain clinical trial costs.

Consulting and outside services decreased from approximately $1.5 million for the six months ended December 31, 2019 to approximately $0.3 million for the six months ended December 31, 2020, a decrease of $1.2 million. For the six months ended December 31, 2019, our consulting spending primarily consisted of $0.4 million related to RZ358, $0.8 million for RZ402, and $0.2 million for patent maintenance costs. For the six months ended December 31, 2020, consulting and outside services of $0.3 million was primarily related to RZ358 and patent maintenance costs.

Licensing costs increased by $1.0 million for the six months ended December 31, 2020 compared to the six months ended December 31, 2019, which was attributable to the $1.0 million milestone payment due to ActiveSite upon FDA clearance of our RZ402 IND application.

Material manufacturing costs decreased from approximately $0.4 million for the six months ended December 31, 2019 to $0.3 million for the six months ended December 31, 2020, a decrease of $0.1 million. The decrease in our material manufacturing costs was primarily due to decreased spending in RZ358 for CMC drug product stability and storage.

Costs allocable to R&D activities for facilities and other costs decreased from approximately $0.3 million for the six months ended December 31, 2019 to approximately $0.1 million for the six months ended December 31, 2020. The decrease was primarily attributable to reduced spending for travel and generally lower overall levels of R&D activity associated with the COVID-19 pandemic for the six months ended December 31, 2020.

General and administrative expenses. G&A expenses increased from approximately $3.6 million for the six months ended December 31, 2019 to approximately $3.9 million for the six months ended December 31, 2020, an increase of $0.3 million. This increase was primarily attributable to increases in compensation and benefits for our administrative and executive workforce of $0.3 million.

The increase of $0.3 million in compensation and benefits was primarily attributable to an increase in cash-based compensation of $0.5 million, partially offset by a decrease in stock-based compensation expense of $0.2 million. Cash-based compensation increased by $0.5 million for the six months ended December 31, 2020 primarily due to annual performance bonuses earned by members of our G&A workforce offset partially by the receipt of the CARES Act employee retention credit in September 2020. Stock-based compensation decreased by $0.2 million primarily due to certain stock options were forfeited or became fully vested by December 2019, resulting in no further compensation expense after that date.

For the six months ended December 31, 2020, professional fees increased by $0.2 million, primarily due to increased spending on investor relations connected with the Nasdaq uplisting and related transactions.

Our facilities and other costs decreased by approximately $0.2 million for the six months ended December 31, 2020, primarily due to reduced travel and office-related expenses due to COVID-19 restrictions and a reduction in property tax expense.

Income Taxes. For the six months ended December 31, 2020 and 2019, we did not recognize any income tax benefit due to our net losses and our determination that a full valuation allowance was required for our deferred tax assets.

Liquidity and Capital Resources

As of December 31, 2020, we had cash and cash equivalents totaling approximately $37.6 million and working capital was approximately $35.4 million. We have incurred cumulative net losses of $158.0 million since our inception, and as a clinical stage company we have not generated any revenue to date.

As discussed below under Fiscal 2021 Financing, on October 9, 2020 we received aggregate net proceeds from investors in a private placement of approximately $37.5 million from the issuance of units that consisted of approximately 2.5 million shares of Common Stock and warrants for the purchase of approximately 0.8 million shares of Common Stock. We believe our existing cash and cash equivalents balance will be adequate to carry out currently planned activities at least through March 31, 2022. We also have flexibility to delay future clinical programs to conserve our capital resources.

Beginning in March 2020, COVID-19 has resulted in an economic environment that is unfavorable for many businesses to conduct operations. The U.S. economy had been adversely affected by mass quarantines and government mandated stay-in-place orders to halt the spread of the virus. While these orders have been relaxed at times, a full recovery of the U.S. economy may not occur until after 2021. The long-term effects on us are expected to result in higher costs in order to comply with safeguards to protect patients and staff engaged in clinical activities, and extended periods of time may be required to complete clinical trials. The current economic environment and financial market volatility may make it more challenging for us to continue to obtain funding in the future for our clinical programs.

Presented below is further discussion of recent developments that impacted our liquidity and capital resources.

Fiscal 2021 Financing

On October 9, 2020, we completed a private placement of units (the “Units”) consisting of (i) approximately 2.5 million shares of Common stock, and (ii) warrants entitling the holders to purchase approximately 0.8 million shares of Common Stock (the “Warrants”). The Warrants are exercisable at $19.50 per share for a period of 7 years and may be exercised on a cash or cashless basis at the election of the holders. The Units were issued for a purchase price of $16.50 per Unit, resulting in gross proceeds of $41.0 million. Pursuant to a financial advisory agreement, we agreed to pay the advisors a fee of 6.0% of the gross proceeds, and costs for professional fees and other offering costs amounted to approximately $1.1 million. After deducting the financial advisory fees and other offering costs, the estimated net proceeds amounted to approximately $37.5 million. Pursuant to the terms of the private placement, we executed the Reverse Stock Split, which was previously approved by the stockholders at our annual meeting on October 23, 2019 and that was effective on October 9, 2020. In addition, we were required to use commercially reasonable efforts to (i) list our shares of Common Stock for trading on the Nasdaq Capital Market which was approved by Nasdaq on November 3, 2020, (ii) register the shares of Common Stock included in the Units, and (iii) register the shares of Common Stock issuable upon exercise of the warrants. The Company successfully registered the units on November 27, 2020.

Xoma License Agreement

In December 2017, we entered into a license agreement (“License Agreement”) with XOMA Corporation (“Xoma”) pursuant to which Xoma granted us an exclusive global license to develop and commercialize RZ358 for all indications. In January 2019, the License Agreement was amended. The amended License Agreement set forth an updated payment schedule, as well as revised the amount we were required to expend on development of RZ358 and related licensed products.

On March 31, 2020, we entered into Amendment No. 3 to the License Agreement to extend the previous payment schedule for the remaining balance of approximately $2.6 million. The revised payment schedule provided for seven quarterly payments to be paid beginning on March 31, 2020, whereby the outstanding balance was reduced to $1.4 million as of September 30, 2020. Pursuant to Amendment No. 3, we were obligated to repay the remaining outstanding balance within 15 days following the closing of a financing for $20.0 million or more. Accordingly, the completion of the Fiscal 2021 Financing resulted in acceleration of the $1.4 million outstanding obligation, which was paid in full on October 23, 2020.

Upon the achievement of certain clinical and regulatory events, we will be required to make up to $37.0 million in aggregate milestone payments to Xoma. The first such milestone payment of $2.0 million will be triggered upon enrollment of the last patient in our ongoing phase 2 clinical study and we believe that, subject to COVID-19 conditions, we will be able to complete this study by the second half of calendar year 2021. Additionally, upon the future commercialization of RZ358, we will be required to pay royalties to Xoma based on the net sales of the related products, and milestone payments up to an additional $185.0 million if future annual sales related to RZ358 exceed targets ranging from $100.0 million to $1.0 billion.

ActiveSite License Agreement

In August 2017, we entered into a Development and License Agreement with ActiveSite Pharmaceuticals, Inc. (“ActiveSite”) pursuant to which we acquired the rights to ActiveSite’s Plasma Kallikrein Inhibitor program (“PKI Program”). We are planning to use the PKI Program to develop, file, manufacture, market and sell products for diabetic macular edema and other human therapeutic indications. The ActiveSite Development and License Agreement requires various milestone payments ranging from $1.0 million to $10.0 million when milestone events occur, up to $46.5 million of aggregate milestone payments. The first milestone payment for $1.0 million was paid in December 2020 after we had received clearance from the FDA related to an IND for RZ402. We will also be required to pay royalties equal to 2.0% of any sales of products that use the PKI Program.

Cash Flows Summary

Presented below is a summary of our operating, investing and financing cash flows for the six months ended December 31, 2020 and 2019 (in thousands):

	2020			2019			Change
Net cash provided by (used in):
Operating activities	$	(9,814	)	$	(14,411	)	$	4,597
Investing activities		-			-			-
Financing activities		37,459			22,550			14,909

Cash Flows Used in Operating Activities

For the six months ended December 31, 2020 and 2019, cash flows used in operating activities amounted to $9.8 million and $14.4 million, respectively. The key components in the calculation of our cash used in operating activities are as follows (in thousands):

	2020			2019			Change

Net loss	$	(10,717	)	$	(11,746	)	$	1,029
Non-cash expenses		1,933			2,277			(344	)
Changes in operating assets and liabilities, net		(1,030	)		(4,942	)		3,912
Total	$	(9,814	)	$	(14,411	)	$	4,597

For the six months ended December 31, 2020, our net loss was $10.7 million compared to $11.7 million for the six months ended December 31, 2019. For further discussion about changes in our operating results for the six months ended December 31, 2020 and 2019, please refer to Results of Operations above.

For the six months ended December 31, 2020 and 2019, our non-cash expenses of $1.9 million and $2.2 million, respectively, were primarily attributable to stock-based compensation expense. For the six months ended December 31, 2020, net changes in operating assets and liabilities decreased operating cash flow by $1.0 million, primarily driven by a $1.8 million decrease in payables to Xoma under the amended License Agreement, partially offset by a net increase of $0.8 million in accounts payables and accrued liabilities. For the six months ended December 31, 2019, net changes in operating assets and liabilities reduced operating cash flow by $4.9 million which was primarily due to a $5.9 million decrease in payables to Xoma under the amended License Agreement. This use of operating cash flow was partially offset by a net increase in accounts payable and accrued liabilities of $0.5 million and a decrease in prepaid expenses and other assets of $0.4 million.

Cash Flows Provided by Investing Activities

We did not have any cash flows from investing activities for the six months ended December 31, 2020 and 2019.

Cash Flows Provided by Financing Activities

Net cash provided by financing activities for the six months ended December 31, 2020 was $37.5 million. This amount consisted of $41.0 million received from a private placement of Units in October 2020 for the purchase of approximately 2.5 million shares of Common Stock at a purchase price of $16.50 per share partially offset by financial advisory fees and offering costs of approximately $3.5 million to result in net proceeds of $37.5 million.

Net cash provided by financing activities for the six months ended December 31, 2019 amounted to $22.6 million. This amount consisted of (i) $20.0 million received from Handok, Inc. and Genexine, Inc. in July 2019 for the purchase of approximately 1.4 million shares of Common Stock at a purchase price of $14.50 per share and (ii) $4.1 million received from other investors in July and August 2019 for the purchase of approximately 0.3 million shares of our Common Stock at a purchase price of $14.50 per share. The gross proceeds from these equity issuances totaled $24.1 million and were partially offset by offering costs of $1.5 million to result in net proceeds of $22.6 million.

Recent Accounting Pronouncements

Please refer to Note 1 in Part I, Item 1 of this Report regarding the impact of certain accounting pronouncements on our unaudited condensed consolidated financial statements.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet transactions for the periods covered by this Report.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not required for smaller reporting companies.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (our principal executive and financial officer), of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (“Exchange Act”). Based on that assessment under those criteria, our management has determined that, as of December 31, 2020, our internal control over financial reporting was not effective due to a material weakness in the system of internal control. A material weakness is a deficiency, or combination of deficiencies, that creates a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected in a timely manner.

The material weakness identified by management is that due to our limited number of employees, we have not adequately segregated certain duties to prevent employees from overriding the internal control system. During our fiscal year ended June 30, 2020, we hired a Director of Accounting and we implemented additional procedures to improve our segregation of duties. However, without hiring additional personnel we have been unable to fully remediate this material weakness. We cannot provide assurance that these or other measures will eventually result in the elimination of the material weakness described above.

Changes in internal controls over financial reporting

During the period covered by this Quarterly Report on Form 10-Q, there were no changes in our internal control over financial reporting (as defined in Rule 13(a)-15(f) or 15(d)-15(f)) that occurred during the period covered by this quarterly report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

None

ITEM 1A. RISK FACTORS.

Certain factors exist which may affect the Company’s business and could cause actual results to differ materially from those expressed in any forward-looking statements. Factors that could cause our actual results to differ materially from those in this Report are any of the risks described in Item 1.A. Risk Factors of our 2020 Form 10-K, and the risk factor discussed below. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.

COVID-19 could continue to adversely impact our business, including our clinical trials.

Beginning in March 2020, COVID-19 has resulted in an economic environment that is unfavorable for many businesses to conduct operations and to pursue new debt and equity financings. The U.S. economy has been adversely affected by mass quarantines and government mandated stay-in-place orders to halt the spread of the virus. While these orders have been relaxed, a full recovery of the U.S. economy may not occur until the second half of 2021 or later. The extent to which COVID-19 may continue to impact our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. As COVID-19 continues to spread around the globe, we will likely experience disruptions that could severely impact our business and clinical trials, including:

	·	delays or difficulties in enrolling patients or maintaining scheduled study visits in our clinical trials;
	·	delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;
	·	diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;
	·	interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others;
	·	limitations in employee resources that would otherwise be focused on the conduct of our business or our clinical trials, including because of sickness of employees or their families, the desire of employees to avoid contact with large groups of people or as a result of the governmental imposition of “shelter in place” or similar working restrictions;
	·	delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;
	·	delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;
	·	interruption in global shipping that may affect the transport of clinical trial materials, such as investigational drug product used in our clinical trials;
	·	changes in local regulations as part of a response to the COVID-19 outbreak which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;
	·	delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and
	·	refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.

COVID-19 is currently impacting countries, communities and markets. We require ongoing access to the capital markets to fund our future capital requirements. To the extent that our access to the capital markets is adversely affected by COVID-19, we may need to consider alternative sources of funding for our operations and for working capital, any of which could increase our cost of capital.

Our Certificate of Incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for certain litigation that may be initiated by our stockholders, including claims under the Securities Act, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our Certificate of Incorporation provides that the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws or (iv) any action asserting a claim governed by the internal affairs doctrine. The choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the State of Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find the choice of forum provision contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. Notwithstanding the foregoing, the exclusive provision shall not preclude or contract the scope of exclusive federal or concurrent jurisdiction for actions brought under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, or the respective rules and regulations promulgated thereunder.”

If we are not able to comply with the applicable continued listing requirements or standards of Nasdaq, Nasdaq could delist our Common Stock.

Our Common Stock is currently listed on Nasdaq. In order to maintain such listing, we must satisfy minimum financial and other continued listing requirements and standards, including those regarding director independence and independent committee requirements, minimum stockholders’ equity, minimum share price, and certain corporate governance requirements.

On December 28, 2020, the Company notified Nasdaq that it was not in compliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)(A) as a result of the resignation of a member of the Company’s board who was also a member of the Company’s Audit Committee. Nasdaq Listing Rule 5605(b)(1) requires a majority independent board and 5605(c)(2)(A) requires the Audit Committee to have at least three independent members (as defined by Nasdaq Listing Rule 5605(a)(2) and Rule 10A-3(b)(1) under the Securities Exchange Act of 1934), at least one of whom is an audit committee financial expert. As a result of the resignation of Mr. Jung-Hee Lim, the Company no longer has a majority independent board or an Audit Committee comprised of three independent directors. The Nasdaq Listing Rules provide for a cure period during which the Company may regain compliance. Under Nasdaq Listing Rules, the Company shall have until the earlier of its next annual meeting of stockholders or one year from the occurrence of the event that caused the failure to comply with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)(A); provided, however, that if the next annual meeting of stockholders occurs no later than 180 days following the event that caused the vacancy, the Company shall instead have 180 days from such event to regain compliance.

There can be no assurances that we will be able to regain compliance with Nasdaq’s listing standards or if we do later regain compliance with Nasdaq’s listing standards, will be able to continue to comply with the applicable listing standards. If we are unable to maintain compliance with these Nasdaq requirements, our Common Stock will be delisted from Nasdaq.

If Nasdaq delists our Common Stock, we could face significant material adverse consequences, including:

	·	a limited availability of market quotations for our securities;

	·	a determination that our Common Stock is a “penny stock” which will require brokers trading in our Common Stock to adhere to more stringent rules and possibly resulting in a reduced level of trading activity in the secondary trading market for our Common Stock;

	·	a limited amount of news and analyst coverage for our company; and

	·	a decreased ability to issue additional securities or obtain additional financing in the future

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

There were no reportable issuances of unregistered shares of the Company's equity securities for the period covered by this Report.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS.

Exhibit Number		Description of Exhibits
3.1		Certificate of Amendment to Amended and Restated Articles of Incorporation of Rezolute, Inc., dated October 8, 2020 (incorporated by reference to the Company’s 8-K filing on October 13, 2020)
4.1		Form of Common Stock Purchase Warrant by and between the Company and the Investor identified therein (incorporated by reference to the Company’s 8-K filing on October 13, 2020)
10.1		Securities Purchase Agreement, dated as of October 8, 2020, by and between Rezolute. Inc. and the investors identified therein (incorporated by reference to the Company’s Form 8-K filing on October 13, 2020)
10.2		Registration Rights Agreement, dated as of October 8, 2020, by and between Rezolute, Inc., and the Investors identified therein (incorporated by reference to the Company’s Form 8-K filing on October 13, 2020)
31.1*		Certification of Chief Executive and Principal Financial Officer as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1*		Certification of Chief Executive and Principal Financial Officer as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
101.INS*		XBRL Instance Document
101.SC*		XBRL Taxonomy Extension Schema
101.CA*		XBRL Taxonomy Extension Calculation Linkbase
101.DEF*		XBRL Taxonomy Extension Definition Linkbase
101.LA*		XBRL Taxonomy Extension Label Linkbase
101.PRE*		XBRL Taxonomy Extension Presentation Linkbase

____________________

* Filed herewith.

SIGNATURES

In accordance with Section 12 of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		REZOLUTE, INC.

Date: February 10, 2021	By:	/s/ Nevan Elam
		Nevan Elam
		Chief Executive Officer
		(Principal Executive and Financial Officer)

EX-31.1 2 tm214780d1_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Nevan Elam, certify that:

I have reviewed this quarterly report on Form 10-Q of Rezolute, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report.

As the Registrant's certifying officer, I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

As the Registrant's certifying officer, I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors:

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Date: February 10, 2021

	By:	/s/ Nevan Elam
		Nevan Elam
		Chief Executive Officer (Principal Executive and Financial Officer)

EX-32.1 3 tm214780d1_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Rezolute, Inc. (the “Company”) on Form 10-Q for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nevan Elam, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 10, 2021

	By:	/s/ Nevan Elam
		Nevan Elam
		Chief Executive Officer (Principal Executive and Financial Officer)

A signed original of this written statement required by Section 906 has been provided to Rezolute, Inc. and will be retained by Rezolute, Inc. to be furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 4 rzlt-20201231.xml XBRL INSTANCE DOCUMENT 0001509261 srt:MaximumMember rzlt:OtherInvestorsMember 2019-06-19 2019-06-19 0001509261 us-gaap:InvestorMember 2019-06-19 2019-06-19 0001509261 us-gaap:LicenseAgreementTermsMember 2020-03-01 2020-03-31 0001509261 rzlt:XomaMember us-gaap:LicenseAgreementTermsMember 2020-07-01 2020-12-31 0001509261 us-gaap:InvestorMember 2020-12-31 2020-12-31 0001509261 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001509261 us-gaap:CommonStockMember 2020-07-01 2020-12-31 0001509261 us-gaap:InvestorMember 2019-07-01 2019-07-23 0001509261 us-gaap:InvestorMember 2020-10-09 2020-10-09 0001509261 srt:MinimumMember 2020-10-23 2020-10-23 0001509261 srt:MaximumMember 2020-10-23 2020-10-23 0001509261 2020-10-07 2020-10-07 0001509261 us-gaap:RetainedEarningsMember 2020-12-31 0001509261 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001509261 us-gaap:RetainedEarningsMember 2020-09-30 0001509261 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001509261 2020-09-30 0001509261 us-gaap:RetainedEarningsMember 2020-06-30 0001509261 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001509261 us-gaap:RetainedEarningsMember 2019-12-31 0001509261 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001509261 us-gaap:RetainedEarningsMember 2019-09-30 0001509261 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001509261 2019-09-30 0001509261 us-gaap:RetainedEarningsMember 2019-06-30 0001509261 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001509261 us-gaap:CommonStockMember 2020-12-31 0001509261 us-gaap:CommonStockMember 2020-09-30 0001509261 us-gaap:CommonStockMember 2020-06-30 0001509261 us-gaap:CommonStockMember 2019-12-31 0001509261 us-gaap:CommonStockMember 2019-09-30 0001509261 us-gaap:CommonStockMember 2019-06-30 0001509261 rzlt:OtherInvestorsMember 2019-08-31 0001509261 us-gaap:InvestorMember 2019-07-23 0001509261 rzlt:HybridBasedStockOptionsVestingMember 2020-07-01 2020-12-31 0001509261 rzlt:Year2019PlanMember 2020-12-31 0001509261 rzlt:Year2016PlanMember 2020-12-31 0001509261 rzlt:Year2015PlanMember 2020-12-31 0001509261 rzlt:Year2014PlanMember 2020-12-31 0001509261 rzlt:NonQualifiedStockOptionPlanMember rzlt:EmployeesAndDirectorsMember 2019-07-31 0001509261 us-gaap:WarrantMember 2020-07-01 2020-12-31 0001509261 us-gaap:InvestorMember rzlt:MasterServicesAgreementMember 2020-07-01 2020-12-31 0001509261 2019-01-01 2019-01-31 0001509261 2020-10-09 2020-10-09 0001509261 rzlt:XomaMember 2020-10-01 2020-10-31 0001509261 us-gaap:InvestorMember 2019-07-23 2019-07-23 0001509261 us-gaap:PrivatePlacementMember 2019-07-01 2020-06-30 0001509261 rzlt:OtherInvestorsMember 2019-07-01 2019-08-31 0001509261 2019-07-01 2020-06-30 0001509261 2020-10-28 0001509261 rzlt:MasterServicesAgreementMember 2019-07-01 2019-12-31 0001509261 us-gaap:HybridInstrumentMember 2020-11-02 0001509261 rzlt:ScenarioThreeMember us-gaap:EmployeeStockOptionMember us-gaap:HybridInstrumentMember 2020-09-30 0001509261 rzlt:EquityDistributionAgreementMember 2020-12-31 0001509261 2020-10-07 0001509261 2019-08-31 0001509261 us-gaap:InvestorMember 2020-10-09 0001509261 2019-06-30 0001509261 2019-12-31 0001509261 us-gaap:WarrantMember 2020-07-01 2020-12-31 0001509261 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-12-31 0001509261 us-gaap:WarrantMember 2019-10-01 2019-12-31 0001509261 us-gaap:EmployeeStockOptionMember 2019-10-01 2019-12-31 0001509261 us-gaap:ResearchAndDevelopmentExpenseMember 2020-10-01 2020-12-31 0001509261 us-gaap:GeneralAndAdministrativeExpenseMember 2020-10-01 2020-12-31 0001509261 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-12-31 0001509261 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-12-31 0001509261 rzlt:ScenarioTwoMember us-gaap:EmployeeStockOptionMember us-gaap:HybridInstrumentMember 2020-07-01 2020-09-30 0001509261 us-gaap:ResearchAndDevelopmentExpenseMember 2019-10-01 2019-12-31 0001509261 us-gaap:GeneralAndAdministrativeExpenseMember 2019-10-01 2019-12-31 0001509261 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-12-31 0001509261 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-12-31 0001509261 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001509261 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001509261 us-gaap:RetainedEarningsMember 2020-07-01 2020-12-31 0001509261 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-12-31 0001509261 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0001509261 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0001509261 us-gaap:RetainedEarningsMember 2019-07-01 2019-12-31 0001509261 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-12-31 0001509261 us-gaap:CommonStockMember 2019-07-01 2019-12-31 0001509261 rzlt:Year2015PlanMember 2020-02-23 0001509261 rzlt:Year2014PlanMember 2019-03-21 0001509261 rzlt:StockOptionVestingBasedOnTimeMember 2020-07-01 2020-12-31 0001509261 rzlt:HandokMember 2020-12-31 0001509261 rzlt:GenexineMember 2020-12-31 0001509261 us-gaap:InvestorMember 2020-07-01 2020-12-31 0001509261 us-gaap:InvestorMember us-gaap:PrivatePlacementMember 2019-10-01 2019-12-31 0001509261 rzlt:RelatedPartyLicensingAgreementMember 2020-09-15 2020-09-15 0001509261 rzlt:EquityDistributionAgreementMember 2020-12-18 2020-12-18 0001509261 rzlt:XomaMember 2020-10-23 2020-10-23 0001509261 2020-10-28 2020-10-28 0001509261 us-gaap:EmployeeStockOptionMember us-gaap:HybridInstrumentMember 2019-07-01 2019-07-31 0001509261 rzlt:ActivesitePharmaceuticalsIncMember 2020-12-01 2020-12-31 0001509261 rzlt:XomaMember 2020-07-01 2020-12-31 0001509261 2020-12-31 0001509261 2020-06-30 0001509261 rzlt:ActivesitePharmaceuticalsIncMember 2020-07-01 2020-12-31 0001509261 rzlt:ActivesitePharmaceuticalsIncMember 2020-12-31 0001509261 rzlt:XomaMember us-gaap:PutOptionMember us-gaap:LicenseAgreementTermsMember 2020-07-01 2020-12-31 0001509261 2020-10-01 2020-12-31 0001509261 2019-10-01 2019-12-31 0001509261 2019-07-01 2019-12-31 0001509261 us-gaap:InvestorMember 2019-07-01 2019-08-31 0001509261 us-gaap:InvestorMember 2020-12-31 0001509261 us-gaap:InvestorMember 2019-08-31 0001509261 us-gaap:InvestorMember 2020-09-16 2020-09-16 0001509261 2021-02-08 0001509261 2020-07-01 2020-12-31 utr:sqft rzlt:item iso4217:USD xbrli:shares iso4217:USD xbrli:pure xbrli:shares false --06-30 Q2 2021 2020-12-31 10-Q 0001509261 8352277 Yes false Non-accelerated Filer Yes Rezolute, Inc. false true Common Stock, par value $0.001 NASDAQ RZLT 0.060 1500000 2500000 0.060 0.060 820000 2317000 981000 2648000 1943000 3168000 1750000 3336000 2124000 1458000 972000 274000 132000 Xoma was permitted to exercise the Put Option for up to a total of 50,000 shares of Common Stock for the calendar year ending December 31, 2020, and up to an additional 50,000 shares thereafter. 1000000 0.020 677000 428000 436000 232000 292000 140000 141000 83000 0 7000 0 10000 -5891000 -1809000 <div> <div> The carrying value of right-of-use (“ROU”) assets and operating lease liabilities are as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Right-of-Use Assets, net </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 547 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 383 </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Operating Lease Liabilities: </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Current </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 316 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 245 </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Long-term </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 281 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 165 </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 597 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 410 </td> </tr> </table></div>   <div /></div> </div> <div> <div> NOTE 4 — LICENSE AGREEMENTS Xoma License Agreement In December 2017, the Company entered into a license agreement (“License Agreement”) with XOMA Corporation (“Xoma”), through its wholly-owned subsidiary, XOMA (US) LLC, pursuant to which Xoma granted an exclusive global license to the Company to develop and commercialize Xoma 358 (formerly X358, now RZ358) for all indications. In January 2019, the License Agreement was amended. with an updated payment schedule, as well as revising the amount the Company was required to expend on development of RZ358 and related licensed products, and revised provisions with respect to the Company’s diligence efforts in conducting clinical studies. On March 31, 2020, the parties entered into Amendment No. 3 to the License Agreement to extend the payment schedule for the remaining balance of approximately $2.6 million. The revised payment schedule provided for seven quarterly payments to be paid from March 31, 2020 through September 30, 2021.   As discussed in Note 5, the Company completed a private placement of equity securities for gross proceeds of $41.0 million in October 2020, which resulted in acceleration of the entire obligation. On October 23, 2020, the Company paid the outstanding balance of $1.4 million. As of December 31, 2020, the Company does not have any remaining balance payable under Amendment No. 3 to the License Agreement. Upon the achievement of certain clinical and regulatory events, the Company will be required to make up to $37.0 million in aggregate milestone payments to Xoma. In addition to the License Agreement between the Company and Xoma in December 2017, both parties also entered into a stock purchase agreement (“Stock Purchase Agreement”). As of December 31, 2020, Xoma owns approximately  162,000 shares of the Company’s Common Stock. The Stock Purchase Agreement provided Xoma with the right and option to require the Company to use its best efforts to facilitate orderly sales of the shares to a third party or purchase the shares (the “Put Option”). Xoma was permitted to  exercise the Put Option for up to a total of 50,000 shares of Common Stock for the calendar year ending December 31, 2020, and up to an additional 50,000 shares thereafter. On November 3, 2020, the Company’s shares of Common Stock were approved for listing on the Nasdaq Capital Market and the Put Option terminated pursuant to the terms of the Stock Purchase Agreement. ActiveSite License Agreement On August 4, 2017, the Company entered into a Development and License Agreement with ActiveSite Pharmaceuticals, Inc.  (“ActiveSite”) pursuant to which the Company acquired the rights to ActiveSite’s Plasma Kallikrein Inhibitor program (“PKI Portfolio”). The Company is initially using the PKI Portfolio to develop an oral PKI therapeutic for diabetic macular edema (RZ402) and may use the PKI Portfolio to develop other therapeutics for different indications. The ActiveSite Development and License Agreement requires various milestone payments up to $46.5 million. The first milestone payment for $1.0 million was due after acceptance of an Initial Drug Application, or IND, filed with the U.S. Food and Drug Administration (“FDA”). The Company is also required to pay royalties equal to 2.0% of any sales of products that use the PKI Portfolio. On October 28, 2020, the Company submitted an IND to the FDA. On December 3, 2020, the Company received FDA clearance for the IND application filed by the Company. This clearance resulted in the Company owing the first milestone payment of $1.0 million, which was paid in December 2020. There have been no events that would result in any royalty payments owed under the ActiveSite Development and License Agreement to date. <div /></div> </div> 1600000 0 209000 0 46500000 37000000 1000000 29.00 3 3 5000 1400000 0.00 0.030 500000 0 P20Y 0.70 4050000 0 20000000 0 22600000 37500000 1100000 10000000 2300000 1600000 0.22 0.24 0 0 0 0 2913000 1922000 1781000 1023000 0 0 1000000 1000000 <div> <div> Reverse Stock Split In August 2019, the Company’s Board of Directors approved a reverse stock split that was subject to stockholder approval at a special meeting that was concluded on October 28, 2019. Stockholders approved the proposal whereby the Board of Directors had the ability at any time on or before October 23, 2020 to execute a reverse stock split and set an exchange ratio between 20 and 100 shares of the Company’s outstanding Common Stock, $0.001 par value per share, into one issued and outstanding share of Common Stock, without any change in the par value per share or the number of shares of Common Stock authorized. On October 7, 2020, the Board of Directors approved a fifty shares into one share reverse stock split of the Company’s $0.001 par value Common Stock (the “Reverse Stock Split”), resulting in the filing with the Delaware Secretary of State of a Certificate of Amendment (the “Amendment”) to the Company’s Articles of Incorporation. The Amendment was effective on October 9, 2020. In connection with the Reverse Stock Split, proportionate adjustments were made to increase the per share exercise prices and decrease the number of shares of Common Stock issuable upon exercise of stock options and warrants whereby approximately the same aggregate price is required to be paid for such securities upon exercise as had been payable immediately preceding the Reverse Stock Split. In addition, any fractional shares that would otherwise be issued as a result of the Reverse Stock Split were rounded up to the nearest whole share. All references in the accompanying unaudited condensed consolidated financial statements to the number of shares of Common Stock and per share amounts have been retroactively adjusted to give effect to the Reverse Stock Split. <div /></div> </div> 0.02 <div> <div> Risks and Uncertainties The Company's operations may be subject to significant risks and uncertainties including financial, operational, regulatory and other risks associated with a clinical stage company, including the potential risk of business failure as discussed further in Note 2, and the future impact of COVID-19 as discussed in Note 7. <div /></div> </div> P9Y9M18D P1Y 43000 88000 30 20 <div> <div> Presented below is a summary as of December 31, 2020 of the number of shares authorized, outstanding, and available for future grants under each of the Company’s stock option plans (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:47.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:15.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Termination </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:33.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of Shares </td> </tr> <tr> <td valign="bottom" style="width:47.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Description </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:15.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Date </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Authorized </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Outstanding </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Available </td> </tr> <tr> <td valign="bottom" style="width:47.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2014 Plan </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> March 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 43 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 43 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:47.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 Plan </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> February 2020 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 88 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 88 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:47.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2016 Plan </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> October 2021 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 560 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 517 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 43 </td> </tr> <tr> <td valign="bottom" style="width:47.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2019 Plan </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> July 2029 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 300 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 300 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:47.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 991 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 948 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 43 </td> </tr> </table></div>   <div /></div> </div> 14.50 14.50 279 1380 4050000 4050000 0 20000000 19998000 2000 0 0.75

893000

612000

188000

154595000

193831000

2059000

665000

1775000

1141000

1500000

3550000

73000

71000

6000

3000

2059000

1134000

925000

665000

314000

351000

500000

1775000

961000

814000

1141000

648000

493000

1884000

960000

924000

2386000

948000

1438000

10965000

38902000

10518000

38154000

18182000

9955000

37600000

11573000

19712000

10000000

9955000

37600000

8139000

27645000

57.46

19.50

35.82

800000

618000

1438000

<div> <div> NOTE 7 — COMMITMENTS AND CONTINGENCIES Commitments Please refer to Note 4 for further discussion of commitments to make milestone payments and to pay royalties under license agreements with Xoma and ActiveSite. COVID-19 In December 2019, COVID-19 was reported to have surfaced in Wuhan, China, and by March 2020 the spread of the virus had resulted in a world-wide pandemic. The U.S. economy has been adversely affected by mass quarantines and government mandated stay-in-place orders to halt the spread of the virus. While these orders are being lifted gradually, a full recovery of the U.S. economy may not occur until 2021 or later. Federal and state governments in the U.S. have approved funding for many programs that may provide financial assistance to individuals and businesses. The Company intends to pursue all material types of government assistance that it may be entitled to. However, no assurance can be provided that the Company will qualify and realize any material benefits from such assistance. COVID-19 has resulted in an economic environment that is unfavorable for many businesses to pursue new equity financings. Accordingly, the current economic environment is expected to present greater challenges for the Company to obtain additional funding for its clinical programs on terms that are acceptable to the Company’s Board of Directors. In February 2020, Rezolute announced the initiation of its Phase 2b trial in congenital hyperinsulinism . New site initiation and enrollment resumed in the quarter ended December 31, 2020. However, similar to many other clinical studies conducted by other companies throughout the world, effects of the pandemic remain uncertain, and no guarantees can be made that hold in future site initiation or enrollment will not be encountered again. There are no mitigation strategies we can employ to help avoid potential timeline delays should there be an extended enrollment pause due to COVID-19. The long-term effects of COVID-19 are expected to require additional safeguards to protect patients and staff engaged in clinical activities, and extended periods of time required to complete clinical trials, both of which are expected to result in higher overall costs. While the current business disruption is expected to be temporary, the long-term financial impact and the duration cannot be reasonably estimated at this time. Legal Matters From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of December 31, 2020, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the Company’s results of operations. At each reporting period, the Company evaluates known claims to determine whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal fees are expensed as incurred. <div /></div> </div>

0.001

500000000

5867000

8352000

5867000

8352000

6000

8000

122000

100000

32000

9000

6000

<div> <div> NOTE 6 — STOCK-BASED COMPENSATION AND WARRANTS Stock Option Plans The Company currently has two active stock option plans consisting of the 2016 Non-Qualified Stock Option Plan, as amended (the “2016 Plan”), and the 2019 Non Qualified Stock Option Plan (the “2019 Plan”). On July 31, 2019, the 2019 Plan was adopted by the Board of Directors and provides authority to grant non-qualified stock options for up to 300,000  shares of the Company’s Common Stock. The Company also has stock options outstanding to purchase up to approximately 43,000  shares of Common Stock under the 2014 Stock and Incentive Plan (the “2014 Plan”) that terminated on March 21, 2019 and approximately 88,000 shares of Common Stock under the 2015 Stock and Incentive Plan (the "2015 Plan") that terminated on February 23, 2020. Stock options outstanding under the 2014 Plan  and the 2015 Plan expire pursuant to their contractual provisions on various dates through 2029. Presented below is a summary as of December 31, 2020 of the number of shares authorized, outstanding, and available for future grants under each of the Company’s stock option plans (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:47.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:15.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:47.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:15.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Termination </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:33.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of Shares </td> </tr> <tr> <td valign="bottom" style="width:47.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Description </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:15.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Date </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Authorized </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Outstanding </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Available </td> </tr> <tr> <td valign="bottom" style="width:47.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2014 Plan </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> March 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 43 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 43 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:47.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 Plan </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> February 2020 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 88 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 88 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:47.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2016 Plan </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> October 2021 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 560 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 517 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 43 </td> </tr> <tr> <td valign="bottom" style="width:47.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2019 Plan </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:15.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> July 2029 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 300 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 300 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:47.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:15.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 991 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 948 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 43 </td> </tr> </table></div>   Stock Options Outstanding The following table sets forth a summary of the stock option activity for options with time-based vesting and hybrid vesting granted under all of the Company’s stock option plans for the six months ended December 31, 2020 (shares in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price (1) </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Term (2) </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">    </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">    </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding, July 1, 2020 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 963 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 33.06 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.1 </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options granted: </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Awards with time-based vesting </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  8 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24.05 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9.8 </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options forfeited: </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Awards with time-based vesting </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (18) </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14.50 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Awards with hybrid vesting conditions </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (5) </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 14.50 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding, December 31, 2020 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 948 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 33.43 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.5 </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested, December 31, 2020 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 514 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 48.56 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6.7 </td> </tr> </table></div> <div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="left"></hr></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 18.00pt;"> (1) </td><td style="width:0pt;"></td><td align="left" valign="top"> Represents the weighted average exercise price.</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 18.00pt;"> (2) </td><td style="width:0pt;"></td><td align="left" valign="top"> Represents the weighted average remaining contractual term for the number of years until the stock options expire.</td></tr></table></div> Stock-based compensation expense for the three and six months ended December 31, 2020 and 2019 is included in compensation and benefits under the following captions in the unaudited condensed consolidated statements of operations (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:57.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> </tr> <tr> <td valign="bottom" style="width:57.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:57.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:57.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 493 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 351 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 814 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 925 </td> </tr> <tr> <td valign="bottom" style="width:57.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 648 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 314 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 961 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,134 </td> </tr> <tr> <td valign="bottom" style="width:57.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,141 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 665 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,775 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,059 </td> </tr> </table></div>   Unrecognized stock-based compensation expense related to stock options that provide solely for time-based vesting is approximately $2.2 million as of December 31, 2020. This amount is expected to be recognized over a remaining weighted average period of 1.7 years. In July 2019, the Company granted employee stock options for approximately  0.2 million shares that commence vesting upon the achievement of market, performance and service conditions (“Hybrid Options”). Total unrecognized compensation cost, net of forfeitures, for the Hybrid Options amounted to approximately $1.9 million as of November 2, 2020. The Hybrid Options will vest ratably over a period of 36 months beginning on the date that all of the following have occurred: (i) the option recipient has been employed by the Company for at least one year, (ii) the Company’s shares of Common Stock have been listed for trading on a national stock exchange, and (iii) such date no later than July 31, 2023, when the Company’s closing stock price exceeds  $29.00 per share for 20 trading days in any consecutive 30 day period. On November 3, 2020, the performance condition to obtain a listing on a national stock exchange was achieved, when the Company’s shares began trading on the Nasdaq Capital Market. Prior to this date, no compensation cost had been recognized for the Hybrid Options as it was not considered probable that the performance condition would be achieved. Upon achievement of the performance condition, the Company recognized the cumulative effect of compensation cost of approximately $0.5 million for the period from the grant date through November 3, 2020. The remainder of the unrecognized compensation related to the Hybrid Options of approximately $1.4 million, will be recognized ratably through July 2024 when the Hybrid Options are expected to be fully vested. Warrants The Company has issued warrants in conjunction with various debt and equity financings and for services. The following table sets forth a summary of the warrant activity for the six months ended December 31, 2020 (shares in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:64.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price(1) </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Term(2) </td> </tr> <tr> <td valign="bottom" style="width:64.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding, July 1, 2020 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 618 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 57.46 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.3 </td> </tr> <tr> <td valign="bottom" style="width:64.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrants issued </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 820 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (3) </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 19.50 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:64.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding, December 31, 2020 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,438 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 35.82 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4.6 </td> </tr> </table></div> <div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="left"></hr></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 18.00pt;"> (1) </td><td style="width:0pt;"></td><td align="left" valign="top"> Represents the weighted average exercise price.</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 18.00pt;"> (2) </td><td style="width:0pt;"></td><td align="left" valign="top"> Represents the weighted average remaining contractual term for the number of years until the warrants expire.</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 18.00pt;"> (3) </td><td style="width:0pt;"></td><td align="left" valign="top"> Represents warrants granted in connection with the October 9, 2020 private placement. The warrants are exercisable for $19.50 per share for a period of 7 years and may be exercised on a cash or cashless basis at the election of the holder.</td></tr></table></div><div /></div> </div>

-2.08

-1.14

-1.54

-0.88

120000

1264000

P1Y8M12D

1400000

1900000

2200000

73000

103000

6000

<div> <div> NOTE 11 — FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Fair Value Measurements Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair measurement: Level 1—Quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. Level 2—Other than quoted prices included in Level 1 that are observable for the asset and liability, either directly or indirectly through market corroboration, for substantially the full term of the asset or liability. Level 3—Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any market activity for the asset or liability at the measurement date. Due to the relatively short maturity of the respective instruments, the fair value of cash and cash equivalents, accounts payable and accrued liabilities approximated their carrying values as of December 31, 2020 and June 30, 2020. The Company did not have any assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 and June 30, 2020. The Company’s policy is to recognize asset or liability transfers among Level 1, Level 2 and Level 3 as of the actual date of the events or change in circumstances that caused the transfer. During the three and six months ended December 31, 2020 and 2019, the Company did not have any transfers of its assets or liabilities between levels of the fair value hierarchy. Significant Concentrations Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash and cash equivalents at high-quality financial institutions. For the six months ended December 31, 2020, cash deposits have exceeded the amount of federal insurance provided on such deposits. As of December 31, 2020 and June 30, 2020, the Company had cash and cash equivalents with a single financial institution with an aggregate balance of $37.6 million and $10.0 million, respectively. The Company has never experienced any losses related to its investments in cash and cash equivalents. <div /></div> </div>

3627000

1682000

3935000

2656000

<div> <div> NOTE 9 — INCOME TAXES Income tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date operating results, plus any significant unusual or infrequently occurring items which are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating results for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known or as the tax environment changes. For the three and six months ended December 31, 2020 and 2019, the Company did not record any income tax benefit due to a full valuation allowance on its deferred tax assets. The Company did not have any material changes to its conclusions regarding valuation allowances for deferred income tax assets or uncertain tax positions for the three and six months ended December 31, 2020 and 2019. <div /></div> </div>

690000

-412000

-164000

1193000

-423000

2000

153000

54000

58000

55000

8700

0.060

false

<div> <div> Future payments under all operating lease agreements as of December 31, 2020 are as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fiscal year ending June 30, </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">    </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Remainder of fiscal year 2021 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 164 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2022 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 283 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2023 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 117 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Thereafter </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 79 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total lease payments </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 643 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Less imputed interest </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (46) </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Present value of operating lease liabilities </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 597 </td> </tr> </table></div>   <div /></div> </div>

643000

283000

79000

117000

164000

46000

P40M

<div> <div> NOTE 3 — OPERATING LEASES The carrying value of right-of-use (“ROU”) assets and operating lease liabilities are as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30, </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Right-of-Use Assets, net </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 547 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 383 </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Operating Lease Liabilities: </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Current </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 316 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 245 </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Long-term </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 281 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 165 </td> </tr> <tr> <td valign="bottom" style="width:70.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 597 </td> <td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 410 </td> </tr> </table></div>   As of December 31, 2020, the weighted average remaining lease term under operating leases was 2.2 years, and the weighted average discount rate for operating lease liabilities was 7.8%. For the three and six months ended December 31, 2020 , cash paid for amounts included in the measurement of operating lease liabilities was $65,000 and $134,000, respectively. For the three and six months ended December 31, 2019, cash paid for amounts included in the measurement of operating lease liabilities amounted was $68,000 and $136,000, respectively. These cash payments were included in the determination of net cash used in operating activities in the condensed consolidated statements of cash flows. On October 28, 2020, the Company entered into an assignment, assumption and amendment of lease agreement for ancillary office space in Bend, Oregon. The leased space consists of approximately 5,000 square feet and provides for average monthly rent of approximately $8,700 through the expiration date in February 2024. The lease provides one option to renew the lease for an additional three years at market rates. The Company determined it was not reasonably assured that this renewal option would be exercised whereby the resulting lease term was estimated at 40 months.  Using a discount rate of 6.0%, the Company recognized a ROU asset and corresponding operating lease liability of approximately $0.3 million at inception of the lease. Future payments under all operating lease agreements as of December 31, 2020 are as follows (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Fiscal year ending June 30, </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">    </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Remainder of fiscal year 2021 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 164 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2022 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 283 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2023 </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 117 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Thereafter </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 79 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total lease payments </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 643 </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Less imputed interest </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (46) </td> </tr> <tr> <td valign="bottom" style="width:84.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Present value of operating lease liabilities </td> <td valign="bottom" style="width:02.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 597 </td> </tr> </table></div>   <div /></div> </div>

3600000

3016000

10965000

38902000

3226000

2735000

441000

254000

308000

134000

<div> <div> Nature of Operations Rezolute, Inc. (the “Company”) is a clinical stage biopharmaceutical company incorporated in Delaware in 2010. <div /></div> </div>

22550000

37459000

-14411000

24200000

-9814000

-11746000

20300000

-6666000

-10717000

-7097000

<div> <div> Recent Accounting Pronouncements Standards Required to be Adopted in Future Years. The following accounting standards are not yet effective; management has not completed its evaluation to determine the impact that adoption of this standard will have on the Company’s consolidated financial statements. In June 2016, the Financial Accounting Standards Board ("FASB”) issued Accounting Standards Update ("ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the guidance on the impairment of financial instruments.  This update adds an impairment model (known as the current expected credit losses model) that is based on expected losses rather than incurred losses.  Under the new guidance, an entity recognizes, as an allowance, its estimate of expected credit losses.  In November 2019, ASU 2016-13 was amended by ASU 2019-10, Financial Instruments- Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) whereby the effective date for ASU 2016-13 for smaller reporting companies is now required for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity). ASU 2020-06 reduces the number of accounting models for convertible debt instruments and convertible preferred stock, which results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Additionally, ASU 2020-06 affects the diluted earnings per share calculation for instruments that may be settled in cash or shares and for convertible instruments and requires enhanced disclosures about the terms of convertible instruments and contracts in an entity's own equity. ASU 2020-06 allows entities to use a modified or full retrospective transition method and is effective for smaller reporting companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not currently expected to have a material impact on the Company's financial statements upon adoption. <div /></div> </div>

11899000

6720000

10775000

7152000

-11899000

-6720000

-10775000

-7152000

136000

139000

410000

300000

597000

245000

316000

165000

281000

136000

68000

134000

65000

383000

300000

547000

0.078

P2Y2M12D

<div> <div> NOTE 1 — NATURE OF OPERATIONS AND SUMMARY OF SIGNFICANT ACCOUNTING POLICIES Nature of Operations Rezolute, Inc. (the “Company”) is a clinical stage biopharmaceutical company incorporated in Delaware in 2010.  Reverse Stock Split In August 2019, the Company’s Board of Directors approved a reverse stock split that was subject to stockholder approval at a special meeting that was concluded on October 28, 2019. Stockholders approved the proposal whereby the Board of Directors had the ability at any time on or before October 23, 2020 to execute a reverse stock split and set an exchange ratio between 20 and 100 shares of the Company’s outstanding Common Stock, $0.001 par value per share, into one issued and outstanding share of Common Stock, without any change in the par value per share or the number of shares of Common Stock authorized. On October 7, 2020, the Board of Directors approved a fifty shares into one share reverse stock split of the Company’s $0.001 par value Common Stock (the “Reverse Stock Split”), resulting in the filing with the Delaware Secretary of State of a Certificate of Amendment (the “Amendment”) to the Company’s Articles of Incorporation. The Amendment was effective on October 9, 2020. In connection with the Reverse Stock Split, proportionate adjustments were made to increase the per share exercise prices and decrease the number of shares of Common Stock issuable upon exercise of stock options and warrants whereby approximately the same aggregate price is required to be paid for such securities upon exercise as had been payable immediately preceding the Reverse Stock Split. In addition, any fractional shares that would otherwise be issued as a result of the Reverse Stock Split were rounded up to the nearest whole share. All references in the accompanying unaudited condensed consolidated financial statements to the number of shares of Common Stock and per share amounts have been retroactively adjusted to give effect to the Reverse Stock Split. Basis of Presentation The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the SEC for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The condensed consolidated balance sheet as of June 30, 2020, has been derived from the Company’s audited consolidated financial statements. The unaudited interim financial statements should be read in conjunction with the Company’s 2020 Form 10-K, which contains the Company’s audited financial statements and notes thereto, together with the Management’s Discussion and Analysis of Financial Condition and Results of Operations for the year ended fiscal June 30, 2020. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnote disclosures necessary for a comprehensive presentation of financial position, results of operations, and cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the three and six months ended December 31, 2020 are not necessarily indicative of the financial condition and results of operations that may be expected for any future interim period or for the fiscal year ending June 30, 2021. Reclassifications Certain amounts in the previously issued comparative interim financial statements for the three and six months ended December 31, 2019 have been reclassified to conform to the current interim financial statement presentation. These reclassifications had no effect on the previously reported net loss, working capital, cash flows and stockholders’ equity. Consolidation The Company has three wholly owned subsidiaries consisting of AntriaBio Delaware, Inc., Rezolute (Bio) Ireland Limited, and Rezolute Bio UK, Ltd. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its three wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and the accompanying notes. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company’s significant accounting estimates include, but are not necessarily limited to, fair value of share-based payments, management’s assessment of going concern, accrued clinical trial liabilities, estimates of the probability and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses. Actual results could differ from those estimates.  Risks and Uncertainties The Company's operations may be subject to significant risks and uncertainties including financial, operational, regulatory and other risks associated with a clinical stage company, including the potential risk of business failure as discussed further in Note 2, and the future impact of COVID-19 as discussed in Note 7. Significant Accounting Policies During the six months ended December 31, 2020, there have been no changes in our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020. Recent Accounting Pronouncements Standards Required to be Adopted in Future Years. The following accounting standards are not yet effective; management has not completed its evaluation to determine the impact that adoption of this standard will have on the Company’s consolidated financial statements. In June 2016, the Financial Accounting Standards Board ("FASB”) issued Accounting Standards Update ("ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the guidance on the impairment of financial instruments.  This update adds an impairment model (known as the current expected credit losses model) that is based on expected losses rather than incurred losses.  Under the new guidance, an entity recognizes, as an allowance, its estimate of expected credit losses.  In November 2019, ASU 2016-13 was amended by ASU 2019-10, Financial Instruments- Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) whereby the effective date for ASU 2016-13 for smaller reporting companies is now required for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity). ASU 2020-06 reduces the number of accounting models for convertible debt instruments and convertible preferred stock, which results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Additionally, ASU 2020-06 affects the diluted earnings per share calculation for instruments that may be settled in cash or shares and for convertible instruments and requires enhanced disclosures about the terms of convertible instruments and contracts in an entity's own equity. ASU 2020-06 allows entities to use a modified or full retrospective transition method and is effective for smaller reporting companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not currently expected to have a material impact on the Company's financial statements upon adoption. <div /></div> </div>

180000

543000

1500000

3541000

0.001

20000000

563000

554000

4100000

3800000

20000000

41000000

25000000

20000000

14500000

633000

273000

851000

481000

-11746000

-10717000

33000

36000

144000

247000

8272000

5038000

6840000

4496000

1500000

1530000

-147236000

-157953000

302000

<div> <div> As of December 31, 2020 and 2019, the following outstanding potential common stock equivalents were excluded from the computation of diluted net loss per share since the impact of inclusion was anti-dilutive (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 79.20%;"> <tr> <td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock options </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 948 </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 960 </td> </tr> <tr> <td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,438 </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 924 </td> </tr> <tr> <td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,386 </td> <td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,884 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> Stock-based compensation expense for the three and six months ended December 31, 2020 and 2019 is included in compensation and benefits under the following captions in the unaudited condensed consolidated statements of operations (in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:57.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Three Months Ended </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Six Months Ended </td> </tr> <tr> <td valign="bottom" style="width:57.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:19.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:57.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:57.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:57.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Research and development </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 493 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 351 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 814 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 925 </td> </tr> <tr> <td valign="bottom" style="width:57.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> General and administrative </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 648 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 314 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 961 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,134 </td> </tr> <tr> <td valign="bottom" style="width:57.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,141 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 665 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,775 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,059 </td> </tr> </table></div>   <div /></div> </div>

<div> <div> The following table sets forth a summary of the stock option activity for options with time-based vesting and hybrid vesting granted under all of the Company’s stock option plans for the six months ended December 31, 2020 (shares in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price (1) </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Term (2) </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">    </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">    </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding, July 1, 2020 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 963 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 33.06 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8.1 </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options granted: </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Awards with time-based vesting </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  8 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 24.05 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 9.8 </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Stock options forfeited: </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Awards with time-based vesting </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (18) </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 14.50 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Awards with hybrid vesting conditions </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (5) </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 14.50 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding, December 31, 2020 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 948 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 33.43 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 7.5 </td> </tr> <tr> <td valign="bottom" style="width:67.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Vested, December 31, 2020 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 514 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 48.56 </td> <td valign="bottom" style="width:02.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 6.7 </td> </tr> </table></div> <div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="left"></hr></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 18.00pt;"> (1) </td><td style="width:0pt;"></td><td align="left" valign="top"> Represents the weighted average exercise price.</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 18.00pt;"> (2) </td><td style="width:0pt;"></td><td align="left" valign="top"> Represents the weighted average remaining contractual term for the number of years until the stock options expire.</td></tr></table></div><div /></div> </div>

<div> <div> The Company has issued warrants in conjunction with various debt and equity financings and for services. The following table sets forth a summary of the warrant activity for the six months ended December 31, 2020 (shares in thousands):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:64.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:64.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price(1) </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Term(2) </td> </tr> <tr> <td valign="bottom" style="width:64.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding, July 1, 2020 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 618 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 57.46 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2.3 </td> </tr> <tr> <td valign="bottom" style="width:64.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Warrants issued </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 820 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (3) </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 19.50 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:64.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Outstanding, December 31, 2020 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,438 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 35.82 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 4.6 </td> </tr> </table></div> <div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="left"></hr></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 18.00pt;"> (1) </td><td style="width:0pt;"></td><td align="left" valign="top"> Represents the weighted average exercise price.</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 18.00pt;"> (2) </td><td style="width:0pt;"></td><td align="left" valign="top"> Represents the weighted average remaining contractual term for the number of years until the warrants expire.</td></tr></table></div> Represents warrants granted in connection with the October 9, 2020 private placement. The warrants are exercisable for $19.50 per share for a period of 7 years and may be exercised on a cash or cashless basis at the election of the holder. <div /></div> </div>

<div> <div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:11.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Additional </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> </tr> <tr> <td valign="bottom" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:19.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Common Stock </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Paid-in </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Accumulated </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Stockholders’ </td> </tr> <tr> <td valign="bottom" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amount </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Capital </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Deficit </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Equity </td> </tr> <tr> <td valign="bottom" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Three Months Ended December 31, 2020: </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balances as of September 30, 2020 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,867 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  6 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 155,232 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (150,856) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,382 </td> </tr> <tr> <td valign="top" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock-based compensation </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,141 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,141 </td> </tr> <tr> <td valign="top" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair value of warrants issued to consultants for services </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  3 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  3 </td> </tr> <tr> <td valign="top" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Issuance of Units for cash </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,485 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  2 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 40,998 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41,000 </td> </tr> <tr> <td valign="top" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Advisory fees and other offering costs </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (3,550) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (3,550) </td> </tr> <tr> <td valign="top" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Issuance of common stock for services </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  7 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  7 </td> </tr> <tr> <td valign="top" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net loss </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (7,097) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (7,097) </td> </tr> <tr> <td valign="top" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balances as of December 31, 2020 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8,352 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  8 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 193,831 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (157,953) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 35,886 </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:42.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Three Months Ended December 31, 2019: </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:42.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balances as of September 30, 2019 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,867 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  6 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 152,595 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (131,983) </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 20,618 </td> </tr> <tr> <td valign="top" style="width:42.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock-based compensation </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 665 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 665 </td> </tr> <tr> <td valign="top" style="width:42.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair value of warrants issued to consultants for services </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 71 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 71 </td> </tr> <tr> <td valign="top" style="width:42.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Net loss </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (6,666) </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (6,666) </td> </tr> <tr> <td valign="bottom" style="width:42.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balances as of December 31, 2019 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,867 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  6 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 153,331 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (138,649) </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 14,688 </td> </tr> </table></div>   <div /></div> </div>

31000

43000

2059000

1775000

P36M

P7Y

300000

991000

43000

88000

560000

300000

43000

200000

8000

963000

948000

43000

88000

517000

300000

33.06

33.43

P8Y1M6D

P7Y6M

P6Y8M12D

514000

48.56

14.50

19.50

24.05

14.50

16.50

4208

5867

8352

<div> <div> Significant Accounting Policies During the six months ended December 31, 2020, there have been no changes in our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020. <div /></div> </div>

800000

1752000

128651000

4000

-126903000

20618000

152595000

6000

-131983000

14688000

153331000

6000

-138649000

7365000

154595000

6000

-147236000

4382000

155232000

6000

-150856000

35886000

193831000

8000

-157953000

<div> <div> NOTE 5 — STOCKHOLDERS’ EQUITY For changes in stockholders’ equity for the six months ended December 31, 2020 and 2019, please refer to the unaudited condensed consolidated statements of stockholders’ equity on page 3. The following table presents changes in stockholders’ equity for the three months ended December 31, 2020 and 2019:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="3" valign="bottom" style="width:11.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Additional </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Total </td> </tr> <tr> <td valign="bottom" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="4" valign="bottom" style="width:19.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Common Stock </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Paid-in </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Accumulated </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Stockholders’ </td> </tr> <tr> <td valign="bottom" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Shares </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Amount </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Capital </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Deficit </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Equity </td> </tr> <tr> <td valign="bottom" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Three Months Ended December 31, 2020: </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balances as of September 30, 2020 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,867 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  6 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 155,232 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (150,856) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 4,382 </td> </tr> <tr> <td valign="top" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock-based compensation </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,141 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,141 </td> </tr> <tr> <td valign="top" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair value of warrants issued to consultants for services </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  3 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  3 </td> </tr> <tr> <td valign="top" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Issuance of Units for cash </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,485 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  2 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 40,998 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 41,000 </td> </tr> <tr> <td valign="top" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Advisory fees and other offering costs </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (3,550) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (3,550) </td> </tr> <tr> <td valign="top" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Issuance of common stock for services </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  7 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  7 </td> </tr> <tr> <td valign="top" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Net loss </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (7,097) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (7,097) </td> </tr> <tr> <td valign="top" style="width:42.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balances as of December 31, 2020 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 8,352 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  8 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 193,831 </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (157,953) </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 35,886 </td> </tr> </table></div>   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:42.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Three Months Ended December 31, 2019: </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:42.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balances as of September 30, 2019 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,867 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  6 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 152,595 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (131,983) </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 20,618 </td> </tr> <tr> <td valign="top" style="width:42.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Stock-based compensation </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 665 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 665 </td> </tr> <tr> <td valign="top" style="width:42.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair value of warrants issued to consultants for services </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 71 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 71 </td> </tr> <tr> <td valign="top" style="width:42.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Net loss </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (6,666) </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (6,666) </td> </tr> <tr> <td valign="bottom" style="width:42.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balances as of December 31, 2019 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5,867 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  6 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 153,331 </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (138,649) </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 14,688 </td> </tr> </table></div>   Equity Distribution Agreement On December 18, 2020, the Company and Oppenheimer & Co. Inc. (the “Agent”) entered into an Equity Distribution Agreement (the “EDA”) that provides for an “at the market offering” for the sale of up to $50.0 million in shares of the Company’s Common Stock (the “Placement Shares”) through the Agent.  The Agent is acting as sales agent and is required to use commercially reasonable efforts to sell all of the Placement Shares requested to be sold by the Company, consistent with the Agent's normal trading and sales practices, on mutually agreed terms between the Agent and the Company. The EDA will terminate when all of the Placement Shares have been sold, or earlier upon the election of either the Company or the Agent. The Company has no obligation to sell any of the Placement Shares under the EDA. The Company intends to use the net proceeds, if any, from amounts sold under the EDA for general corporate purposes, including working capital. Under the terms of the EDA, the Company agreed to pay the Agent a commission equal to 3.0% of the gross sales price of the Placement Shares plus certain expenses incurred by the Agent in connection with the offering. Through December 31, 2020, no shares were sold pursuant to the EDA and no commissions were incurred. As of December 31, 2020, total expenses incurred by the Agent and the Company amounted to an aggregate of $0.1 million and are classified as deferred offering costs in the Company’s unaudited condensed consolidated balance sheet. Reverse Stock Split As discussed in Note 1, the Company effected Reverse Stock Split on October 9, 2020. All references in the accompanying consolidated financial statements to the number of shares of Common Stock and per share amounts have been retroactively adjusted to give effect to the Reverse Stock Split. Fiscal 2021 Financing On September 15, 2020, the Company entered into financial advisory agreements to undertake a private placement of equity or equity equivalent securities (the “Fiscal 2021 Financing”). Pursuant to the financial advisory agreements, the Company agreed to pay transaction fees to the financial advisors for an aggregate of 6.0% of the gross proceeds plus out-of-pocket expenses. In addition, for any financing completed within 60 days of the closing of the Fiscal 2021 Financing, the financial advisors were entitled to additional transaction fees equal to 6.0% of the gross proceeds.  As of December 31, 2020, the advisory agreements were no longer active. On October 9, 2020, the Company completed the Fiscal 2021 Financing through the sale of units (the “Units”) consisting of (i) approximately 2.5 million shares of Common stock, and (ii) warrants entitling the holders to purchase approximately 0.8 million shares of Common Stock (the “Warrants”). The Warrants are exercisable at $19.50 per share for a period of seven years and may be exercised on a cash or cashless basis at the election of the holders. The Units were issued for a purchase price of $16.50 per Unit, resulting in gross proceeds of $41.0 million. Pursuant to the financial advisory agreements, the Company paid transaction fees of $2.5 million, and costs for professional fees and other offering costs amounted to approximately $1.1 million. After deducting the financial advisory fees and other offering costs, the estimated net proceeds amounted to approximately $37.5 million. Pursuant to the terms of the Fiscal 2021 Financing, the Company executed the Reverse Stock Split of fifty shares into one share as discussed in Note 1 and agreed to enable trading of its Common Stock on the Nasdaq Capital Market, whereby the Company’s listing application was approved by Nasdaq on November 3, 2020. The Company also entered into a registration rights agreement (“RRA”), pursuant to which the Company agreed to use commercially reasonable efforts to register (i) the shares of Common Stock included in the Units, and (ii) the shares of Common Stock issuable upon exercise of the warrants. The Company successfully registered the units on November 27, 2020. Fiscal 2020 Private Placement In connection with a Series AA Preferred Stock financing in January 2019, the Company granted call options to Handok, Inc. and Genexine, Inc. (collectively, “H&G”) whereby upon the earlier of (i) December 31, 2020 and (ii) such date that the Company requested H&G to provide additional financing, each investor was entitled to purchase up to $10.0 million of Common Stock at a purchase price equal to the greater of (i) $14.50 per share or (ii) 75% of the volume weighted average closing price (“VWAP”) of the Company’s Common Stock during the thirty consecutive trading days prior to the date of the notice. On June 19, 2019, the Company entered into a financial advisory agreement to undertake a private placement (the “Fiscal 2020 Private Placement”) of (i) the shares of Common Stock issuable under the H&G call options for a total of $20.0 million, plus (ii) up to $10.0 million of equity or equity equivalent securities to be issued to other investors. On July 23, 2019, the Company entered into purchase agreements whereby H&G exercised their call options to purchase an aggregate of approximately 1.4 million shares of Common Stock for gross cash proceeds of $20.0 million at a purchase price of $14.50  per share. In addition, during July and August 2019 other investors purchased an aggregate of approximately 279,000 shares of Common Stock at a purchase price of  $14.50 per share for gross cash proceeds of $4.1 million. Pursuant to the financial advisory agreement, the Company paid a fee of  6.0% of the gross proceeds received from the Fiscal 2020 Private Placement. The total advisory fees and other offering costs amounted to approximately $1.5 million, resulting in net proceeds of $22.6 million for the six months ended December 31, 2019. Restricted Cash One of the investors in the Fiscal 2020 Private Placement purchased approximately  262,000  shares of Common Stock for gross proceeds of $3.8 million. The Company agreed to spend the proceeds for certain research and development activities and for a planned uplisting of the Company’s Common Stock to the Nasdaq Capital Market. For the three and six months ended December 31, 2019, the Company made qualified expenditures of $1.6 million and $2.3 million, respectively. As of December 31, 2019, the restricted cash balance amounted to $1.5 million. The Company expended the remainder of the restricted cash proceeds on qualified activities by March 31, 2020, whereby there were no restrictions on cash balances after that date. <div /></div> </div>

0.02

2500000

1400000

279000

262000

1400000

2485

2500000

189000

162000

5000

18000

2600000

7000

20000000

10000000

41000000

40998000

2000

41000000

40998000

2000

50000000

P2Y3M18D

P4Y7M6D

5646

5866

6956

8045

EX-101.SCH 5 rzlt-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - Unaudited Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impact of adoption (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - OPERATING LEASES - Operating lease agreements (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - RIGHT-OF-USE ASSETS - Operating lease agreements - Cal2 (Details) link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00305 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - LIQUIDITY (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - OPERATING LEASES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - LICENSE AGREEMENTS - Remaining payment obligations (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - LICENSE AGREEMENTS - Additional Information - (Detail) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - STOCKHOLDERS' EQUITY - (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - STOCK-BASED COMPENSATION AND WARRANTS - Stock option plans (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - STOCK-BASED COMPENSATION AND WARRANTS - Stock options outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - STOCK-BASED COMPENSATION AND WARRANTS - Stock based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 40605 - Disclosure - STOCK-BASED COMPENSATION AND WARRANTS - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - EARNINGS PER SHARE - Anti-dilutive (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - LIQUIDITY link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - OPERATING LEASES link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - LICENSE AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - STOCK-BASED COMPENSATION AND WARRANTS link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS link:presentationLink link:calculationLink link:definitionLink 20102 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - OPERATING LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - STOCK-BASED COMPENSATION AND WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - OPERATING LEASES - Assets and operating lease liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 40604 - Disclosure - STOCK-BASED COMPENSATION AND WARRANTS - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 rzlt-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 rzlt-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 rzlt-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Interactive Data Current Entity Current Reporting Status Title of 12(b) Security Entity Filer Category Security Exchange Name Trading Symbol Entity Common Stock, Shares Outstanding Entity Shell Company Entity Emerging Growth Company Entity Small Business Unaudited Condensed Consolidated Balance Sheets Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, end of period Cash and cash equivalents Prepaid Expense and Other Assets, Current Prepaid expenses and other Assets, Current Total current assets Operating Lease, Right-of-Use Asset Right-of-use assets, net Right-of-use assets, net Deferred Costs, Noncurrent Deferred offering costs Deferred offering cost Property, Plant and Equipment, Net Property and equipment, net Security Deposit Lease security deposits Assets Total assets Liabilities and Stockholders' Equity Liabilities and Stockholders' Equity Current liabilities: Accounts Payable, Current Accounts payable Accrued liabilities: Employee-related Liabilities, Current Compensation and benefits Accrued Insurance, Current Insurance premiums Other Liabilities, Current Other It represents of license fees payable current License Fees Payable Current Current portion of license fees payable to Xoma Current portion of payable Operating Lease, Liability, Current Current Current portion of operating lease liabilities Liabilities, Current Total current liabilities Operating Lease, Liability, Noncurrent Long-term Operating lease liabilities, net of current portion It represents of license fees payable Non current License Fees Payable Noncurrent Less long term portion of payable License fees payable to Xoma, net of current portion Liabilities Total liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Notes 4 and 7) Stockholders equity: Stockholders' equity : Preferred Stock, Value, Issued Preferred Stock, $0.001 par value, 20,000 shares authorized; no shares issued and outstanding Common Stock, Value, Issued Common Stock, $0.001 par value, 500,000 shares authorized; 8,352 and 5,867 shares issued and outstanding as of December 31, 2020 and June 30, 2020, respectively Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Balance Balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Statement [Table] Statement [Line Items] Changes in Stockholders? Equity (Deficit) Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares, issued Preferred Stock, Shares Outstanding Preferred stock, shares, outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Condensed Consolidated Statements of Operations Operating Expenses [Abstract] Operating expenses: Research and Development [Abstract] Research and development: Amount of compensation and benefits for research and development during the reporting period. Compensation and benefits for Research and development Compensation and benefits, net of related party reimbursements The costs incurred in clinical trial costs which is component of research and development expenses. Research And Development Expense Clinical Trial Costs Clinical trial costs Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Research And Development, Licensing Costs Licensing costs Amount of Consultants and outside costs during the reporting period. Consultants and outside costs Consulting and outside services Manufacturing Costs Material manufacturing costs Amount of facilities and other for research and development during the reporting period. Facilities and other For Research And Development Facilities and other Research and Development Expense Total research and development General and Administrative Expense [Abstract] General and administrative: Amount of compensation and benefits for general and administrative during the reporting period. Compensation and benefits for General and administrative Compensation and benefits Professional Fees Professional fees Amount of facilities and other for general and administrative during the reporting period. Facilities and other For General And Administrative Facilities and other General and Administrative Expense Total general and administrative Operating Expenses Total operating expenses Operating Income (Loss) Operating loss Interest and Other Income Non-operating income - interest and other Net Income (Loss) Attributable to Parent Net loss Net loss Earnings Per Share, Basic and Diluted Net loss per common share - basic and diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average number of common shares outstanding - basic and diluted (in shares) Condensed Consolidated Statements of Stockholders' Equity Shares, Outstanding Balance (in shares) Balance (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation Adjustments to Additional Paid in Capital, Warrant Issued Fair value of warrants issued to consultants for services Stock Issued During Period, Value, New Issues Issuance of Units for cash Stock Issued During Period, Shares, New Issues Number of shares issued Issuance of Units for cash (In shares) Equity impact of the value of new stock issued to related parties during the period. Stock Issued During Period, Value, New Issues, Related Parties Issuance of common stock for cash: Related parties at $14.50 per share Number of new stock issued to related parties during the period. Stock Issued During Period, Shares, New Issues, Related Parties Issuance of common stock for cash: Related parties at $14.50 per share (in shares) Equity impact of the value of new stock issued to other investors during the period. Stock Issued During Period, Value, New Issues, Other Investors Issuance of common stock for cash: Other investors at $14.50 per share Number of new stock issued to other investors during the period. Stock Issued During Period, Shares, New Issues, Other Investors Issuance of common stock for cash: Other Investors at $14.50 per share (in shares) Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Advisory fees and other offering costs Stock Issued During Period, Value, Issued for Services Issuance of common stock for services Equity impact of the per share value of new stock issued to related parties during the period. Stock Issued During Period, Per Share Value, New Issues, Related Parties Issuance of common stock for cash: Related parties, per share Equity impact of the per share value of new stock issued to other investors during the period. Stock Issued During Period, Per Share Value, New Issues, Other Investors Issuance of common stock for cash: Other investors, per share Condensed Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Share-based Compensation Stock-based compensation expense Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization expense Operating Lease, Cost Non-cash lease expense Average monthly rent Fair Value Adjustment of Warrants Fair value of warrants issued for services Amount of expense (income) related to adjustment to fair value of shares of common stock. Fair Value Adjustment of Shares Fair value of shares of Common Stock issued for services Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Decrease (increase) in prepaid expenses and other assets Increase (Decrease) in Accounts Payable Increase (decrease) in accounts payable Increase (Decrease) in Other Accrued Liabilities Increase (decrease) in other accrued liabilities It represents the increase or decrease in license fee payable. Increase decrease In License Fee Payable Decrease in license fees payable to Xoma Net Cash Provided by (Used in) Operating Activities Net Cash Used In Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities CASH FLOWS FROM INVESTING ACTIVITIES Financing Activities CASH FLOWS FROM FINANCING ACTIVITIES: No definition available Proceeds from Issuance of Common Stock from Related Parties Related parties No definition available Proceeds from Issuance of Common Stock from Other Investors Others Proceeds from Issuance of Common Stock Gross proceeds from issuance of common stock Proceeds from issuance of Units Payments of Stock Issuance Costs Payment of commissions and other deferred offering costs Net Cash Provided by (Used in) Financing Activities Net Cash Provided by Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents, and restricted cash Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract] CASH, CASH EQUIVALENTS AND RESTRICTED CASH: Restricted Cash and Cash Equivalents Restricted cash, end of period SUPPLEMENTAL FINANCIAL INFORMATION SUPPLEMENTARY CASH FLOW INFORMATION: Interest Paid, Including Capitalized Interest, Operating and Investing Activities Cash paid for interest Income Taxes Paid Cash paid for income taxes Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets acquired in exchange for operating lease liabilities Noncash Investing and Financing Items [Abstract] SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Amount of furniture and equipment received as inducement under operating lease. Furniture and Equipment Received as Inducement Under Operating lease Furniture and equipment received as inducement under operating lease Deferred Offering Costs Payable for deferred offering costs NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES No definition available. LIQUIDITY Substantial Doubt about Going Concern [Text Block] LIQUIDITY OPERATING LEASES Lessee, Operating Leases [Text Block] OPERATING LEASES n/a LICENSE AGREEMENTS The entire disclosure for information about License agreements. LICENSE AGREEMENTS [Text block] LICENSE AGREEMENTS STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] STOCKHOLDERS' EQUITY STOCK-BASED COMPENSATION AND WARRANTS Disclosure of Compensation Related Costs, Share-based Payments [Text Block] STOCK-BASED COMPENSATION AND WARRANTS COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] RELATED PARTY TRANSACTIONS INCOME TAXES Income Tax Disclosure [Text Block] INCOME TAXES EARNINGS PER SHARE Earnings Per Share [Text Block] EARNINGS PER SHARE FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Financial Instruments Disclosure [Text Block] FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Nature of Operations [Text Block] Nature of Operations Represents the accounting policy for reverse stock split Reverse Stock Split [ Policy Text Block] Reverse Stock Split Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Reclassification, Policy [Policy Text Block] Reclassifications Consolidation, Policy [Policy Text Block] Consolidation Use of Estimates, Policy [Policy Text Block] Use of Estimates Disclosure of accounting policy for the risks and uncertainties during the reporting period. Risks and Uncertainties [Policy Text Block] Risks and Uncertainties Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements The tabular disclosure of carrying value of ROU assets and operating lease liabilities. Lessee, Operating Lease, Right Of Use Assets And Operating Lease Liabilities Summary of carrying value of ROU assets and operating lease liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Summary of future payments under operating lease agreements Schedule of Stockholders Equity [Table Text Block] Summary of changes in stockholder's equity The tabular disclosure of the number of shares authorized, outstanding, and available for future grants under stock option. Share-based Payment Arrangement, Option, Shares Authorized, Outstanding, and Available for Future Grants Schedule of the number of shares authorized, outstanding, and available for future grants under stock option Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of the stock option activity Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of stock-based compensation expense Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of warrant activity Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Summary of potential common stock equivalents were excluded from the computation of diluted net loss per share New Accounting Pronouncement, Early Adoption [Table] New Accounting Pronouncement, Early Adoption [Line Items] No definition. Nature Of Operations And Significant Accounting Policies [Abstract] Nature of operations and Significant accounting policies Present value of lessee's discounted obligation for lease payments from operating lease after deducting deferred rent liability under the current accounting standard . Operating Lease, Liability, Net of Deferred Rent Liability under Current Accounting Standard Net increase in liabilities due to adoption of new standard Stockholders' Equity Note, Stock Split, Conversion Ratio Reverse stock split, Exchange ratio Represents the number of wholly owned subsidiaries. Number of Wholly Owned Subsidiaries Number of wholly owned subsidiaries Proceeds from Issuance of Private Placement Gross proceeds from private placement of equity shares Proceeds from private placement of equity shares Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants Warrants for the purchase of shares of Common Stock Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Operating Lease, Payments Cash paid for amounts included in measurement of operating lease liabilities it represents information about lease space Operating Lease Space Lease space Operating Leases, Rent Expense Lease and rental expense Lessee, Operating Lease, Existence of Option to Extend [true false] Option to extend the lease Lessee, Operating Lease, Discount Rate Discount rate Lessee, Operating Lease, Renewal Term Renewal term Operating Lease, Liability Operating lease liability Total Present value of operating lease liabilities Assets and Liabilities, Lessee [Abstract] Carrying value of ROU assets and operating lease liabilities Operating Lease, Liability [Abstract] Operating Lease Liabilities: Operating Lease, Weighted Average Remaining Lease Term Operating lease weighted average remaining lease term1 Operating Lease, Weighted Average Discount Rate, Percent Weighted average discount rate Lessee, Operating Lease, Liability, Payment, Due [Abstract] Future lease payments related to operating lease agreements Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Remainder of fiscal year 2021 Lessee, Operating Lease, Liability, to be Paid, Year One 2022 Lessee, Operating Lease, Liability, Payments, Due Year Two 2023 EX-101.PRE 9 rzlt-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Dec. 31, 2020	Feb. 08, 2021
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Registrant Name	Rezolute, Inc.
Entity Central Index Key	0001509261
Current Fiscal Year End Date	--06-30
Entity Interactive Data Current	Yes
Entity Current Reporting Status	Yes
Title of 12(b) Security	Common Stock, par value $0.001
Entity Filer Category	Non-accelerated Filer
Security Exchange Name	NASDAQ
Trading Symbol	RZLT
Entity Common Stock, Shares Outstanding		8,352,277
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	true

XML 11 R2.htm IDEA: XBRL DOCUMENT

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Jun. 30, 2020
Current assets:
Cash and cash equivalents	$ 37,600	$ 9,955
Prepaid expenses and other	554	563
Total current assets	38,154	10,518
Right-of-use assets, net	547	383
Deferred offering costs	122	0
Property and equipment, net	36	33
Lease security deposits	43	31
Total assets	38,902	10,965
Current liabilities:
Accounts payable	612	893
Accrued liabilities:
Compensation and benefits	1,264	120
Insurance premiums	0	188
Other	543	180
Current portion of license fees payable to Xoma	0	1,600
Current portion of operating lease liabilities	316	245
Total current liabilities	2,735	3,226
Operating lease liabilities, net of current portion	281	165
License fees payable to Xoma, net of current portion	0	209
Total liabilities	3,016	3,600
Commitments and contingencies (Notes 4 and 7)
Stockholders' equity :
Preferred Stock, $0.001 par value, 20,000 shares authorized; no shares issued and outstanding
Common Stock, $0.001 par value, 500,000 shares authorized; 8,352 and 5,867 shares issued and outstanding as of December 31, 2020 and June 30, 2020, respectively	8	6
Additional paid-in capital	193,831	154,595
Accumulated deficit	(157,953)	(147,236)
Total stockholders' equity	35,886	7,365
Total liabilities and stockholders' equity	$ 38,902	$ 10,965

XML 12 R3.htm IDEA: XBRL DOCUMENT

Unaudited Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Dec. 31, 2020	Jun. 30, 2020
Unaudited Condensed Consolidated Balance Sheets
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares, issued	0	0
Preferred stock, shares, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	500,000	500,000
Common stock, shares issued	8,352	5,867
Common stock, shares outstanding	8,352	5,867

XML 13 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Research and development:
Compensation and benefits, net of related party reimbursements	$ 2,124	$ 1,750	$ 3,336	$ 3,168
Clinical trial costs	1,023	1,922	1,781	2,913
Licensing costs	1,000	0	1,000	0
Consulting and outside services	132	972	274	1,458
Material manufacturing costs	134	254	308	441
Facilities and other	83	140	141	292
Total research and development	4,496	5,038	6,840	8,272
General and administrative:
Compensation and benefits	1,943	981	2,648	2,317
Professional fees	481	273	851	633
Facilities and other	232	428	436	677
Total general and administrative	2,656	1,682	3,935	3,627
Total operating expenses	7,152	6,720	10,775	11,899
Operating loss	(7,152)	(6,720)	(10,775)	(11,899)
Non-operating income - interest and other	55	54	58	153
Net loss	$ (7,097)	$ (6,666)	$ (10,717)	$ (11,746)
Net loss per common share - basic and diluted (in dollars per share)	$ (0.88)	$ (1.14)	$ (1.54)	$ (2.08)
Weighted average number of common shares outstanding - basic and diluted (in shares)	8,045	5,866	6,956	5,646

XML 14 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Jun. 30, 2019	$ 4	$ 128,651	$ (126,903)	$ 1,752
Balance (in shares) at Jun. 30, 2019	4,208
Stock-based compensation		2,059	0	2,059
Fair value of warrants issued to consultants for services		73	0	73
Issuance of common stock for cash: Related parties at $14.50 per share	$ 2	19,998	0	20,000
Issuance of common stock for cash: Related parties at $14.50 per share (in shares)	1,380
Issuance of common stock for cash: Other investors at $14.50 per share		4,050	0	4,050
Issuance of common stock for cash: Other Investors at $14.50 per share (in shares)	279
Advisory fees and other offering costs		(1,500)	0	(1,500)
Net loss		0	(11,746)	(11,746)
Balance at Dec. 31, 2019	$ 6	153,331	(138,649)	14,688
Balance (in shares) at Dec. 31, 2019	5,867
Balance at Jun. 30, 2019	$ 4	128,651	(126,903)	1,752
Balance (in shares) at Jun. 30, 2019	4,208
Net loss				20,300
Balance at Jun. 30, 2020	$ 6	154,595	(147,236)	7,365
Balance (in shares) at Jun. 30, 2020	5,867
Balance at Sep. 30, 2019	$ 6	152,595	(131,983)	20,618
Balance (in shares) at Sep. 30, 2019	5,867
Stock-based compensation		665	0	665
Fair value of warrants issued to consultants for services		71	0	71
Net loss		0	(6,666)	(6,666)
Balance at Dec. 31, 2019	$ 6	153,331	(138,649)	14,688
Balance (in shares) at Dec. 31, 2019	5,867
Balance at Jun. 30, 2020	$ 6	154,595	(147,236)	7,365
Balance (in shares) at Jun. 30, 2020	5,867
Stock-based compensation		1,775	0	1,775
Fair value of warrants issued to consultants for services		6	0	6
Issuance of Units for cash	$ 2	40,998	0	41,000
Issuance of Units for cash (In shares)	2,485
Advisory fees and other offering costs		(3,550)	0	(3,550)
Issuance of common stock for services		7	0	7
Net loss		0	(10,717)	(10,717)
Balance at Dec. 31, 2020	$ 8	193,831	(157,953)	35,886
Balance (in shares) at Dec. 31, 2020	8,352
Balance at Sep. 30, 2020	$ 6	155,232	(150,856)	4,382
Balance (in shares) at Sep. 30, 2020	5,867
Stock-based compensation		1,141	0	1,141
Fair value of warrants issued to consultants for services		3	0	3
Issuance of Units for cash	$ 2	40,998	0	41,000
Issuance of Units for cash (In shares)	2,485
Advisory fees and other offering costs		(3,550)	0	(3,550)
Issuance of common stock for services		7	0	7
Net loss		0	(7,097)	(7,097)
Balance at Dec. 31, 2020	$ 8	$ 193,831	$ (157,953)	$ 35,886
Balance (in shares) at Dec. 31, 2020	8,352

XML 15 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)	6 Months Ended
	Dec. 31, 2019 $ / shares
Condensed Consolidated Statements of Stockholders' Equity
Issuance of common stock for cash: Related parties, per share	$ 14.50
Issuance of common stock for cash: Other investors, per share	$ 14.50

XML 16 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (10,717)	$ (11,746)
Stock-based compensation expense	1,775	2,059
Depreciation and amortization expense	6	9
Non-cash lease expense	139	136
Fair value of warrants issued for services	6	73
Fair value of shares of Common Stock issued for services	7	0
Changes in operating assets and liabilities:
Decrease (increase) in prepaid expenses and other assets	(2)	423
Increase (decrease) in accounts payable	(412)	690
Increase (decrease) in other accrued liabilities	1,193	(164)
Decrease in license fees payable to Xoma	(1,809)	(5,891)
Net Cash Used In Operating Activities	(9,814)	(14,411)
CASH FLOWS FROM INVESTING ACTIVITIES:
CASH FLOWS FROM INVESTING ACTIVITIES	0	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Related parties	0	20,000
Others	0	4,050
Proceeds from issuance of Units	41,000	0
Payment of commissions and other deferred offering costs	(3,541)	(1,500)
Net Cash Provided by Financing Activities	37,459	22,550
Net increase in cash, cash equivalents and restricted cash	27,645	8,139
Cash, cash equivalents and restricted cash at beginning of period	9,955	11,573
Cash, cash equivalents and restricted cash at end of period	37,600	19,712
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
Cash and cash equivalents, end of period	37,600	18,182
Restricted cash, end of period	0	1,530
Cash, cash equivalents and restricted cash at end of period	37,600	19,712
SUPPLEMENTARY CASH FLOW INFORMATION:
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Right-of-use assets acquired in exchange for operating lease liabilities	302	0
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Furniture and equipment received as inducement under operating lease	10	0
Payable for deferred offering costs	$ 32	$ 0

XML 17 R8.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Dec. 31, 2020
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 — NATURE OF OPERATIONS AND SUMMARY OF SIGNFICANT ACCOUNTING POLICIES Nature of Operations Rezolute, Inc. (the “Company”) is a clinical stage biopharmaceutical company incorporated in Delaware in 2010. Reverse Stock Split In August 2019, the Company’s Board of Directors approved a reverse stock split that was subject to stockholder approval at a special meeting that was concluded on October 28, 2019. Stockholders approved the proposal whereby the Board of Directors had the ability at any time on or before October 23, 2020 to execute a reverse stock split and set an exchange ratio between 20 and 100 shares of the Company’s outstanding Common Stock, $0.001 par value per share, into one issued and outstanding share of Common Stock, without any change in the par value per share or the number of shares of Common Stock authorized. On October 7, 2020, the Board of Directors approved a fifty shares into one share reverse stock split of the Company’s $0.001 par value Common Stock (the “Reverse Stock Split”), resulting in the filing with the Delaware Secretary of State of a Certificate of Amendment (the “Amendment”) to the Company’s Articles of Incorporation. The Amendment was effective on October 9, 2020. In connection with the Reverse Stock Split, proportionate adjustments were made to increase the per share exercise prices and decrease the number of shares of Common Stock issuable upon exercise of stock options and warrants whereby approximately the same aggregate price is required to be paid for such securities upon exercise as had been payable immediately preceding the Reverse Stock Split. In addition, any fractional shares that would otherwise be issued as a result of the Reverse Stock Split were rounded up to the nearest whole share. All references in the accompanying unaudited condensed consolidated financial statements to the number of shares of Common Stock and per share amounts have been retroactively adjusted to give effect to the Reverse Stock Split. Basis of Presentation The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the SEC for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The condensed consolidated balance sheet as of June 30, 2020, has been derived from the Company’s audited consolidated financial statements. The unaudited interim financial statements should be read in conjunction with the Company’s 2020 Form 10-K, which contains the Company’s audited financial statements and notes thereto, together with the Management’s Discussion and Analysis of Financial Condition and Results of Operations for the year ended fiscal June 30, 2020. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnote disclosures necessary for a comprehensive presentation of financial position, results of operations, and cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the three and six months ended December 31, 2020 are not necessarily indicative of the financial condition and results of operations that may be expected for any future interim period or for the fiscal year ending June 30, 2021. Reclassifications Certain amounts in the previously issued comparative interim financial statements for the three and six months ended December 31, 2019 have been reclassified to conform to the current interim financial statement presentation. These reclassifications had no effect on the previously reported net loss, working capital, cash flows and stockholders’ equity. Consolidation The Company has three wholly owned subsidiaries consisting of AntriaBio Delaware, Inc., Rezolute (Bio) Ireland Limited, and Rezolute Bio UK, Ltd. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its three wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and the accompanying notes. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company’s significant accounting estimates include, but are not necessarily limited to, fair value of share-based payments, management’s assessment of going concern, accrued clinical trial liabilities, estimates of the probability and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses. Actual results could differ from those estimates. Risks and Uncertainties The Company's operations may be subject to significant risks and uncertainties including financial, operational, regulatory and other risks associated with a clinical stage company, including the potential risk of business failure as discussed further in Note 2, and the future impact of COVID-19 as discussed in Note 7. Significant Accounting Policies During the six months ended December 31, 2020, there have been no changes in our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020. Recent Accounting Pronouncements Standards Required to be Adopted in Future Years. The following accounting standards are not yet effective; management has not completed its evaluation to determine the impact that adoption of this standard will have on the Company’s consolidated financial statements. In June 2016, the Financial Accounting Standards Board ("FASB”) issued Accounting Standards Update ("ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the guidance on the impairment of financial instruments. This update adds an impairment model (known as the current expected credit losses model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes, as an allowance, its estimate of expected credit losses. In November 2019, ASU 2016-13 was amended by ASU 2019-10, Financial Instruments- Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) whereby the effective date for ASU 2016-13 for smaller reporting companies is now required for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity). ASU 2020-06 reduces the number of accounting models for convertible debt instruments and convertible preferred stock, which results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Additionally, ASU 2020-06 affects the diluted earnings per share calculation for instruments that may be settled in cash or shares and for convertible instruments and requires enhanced disclosures about the terms of convertible instruments and contracts in an entity's own equity. ASU 2020-06 allows entities to use a modified or full retrospective transition method and is effective for smaller reporting companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not currently expected to have a material impact on the Company's financial statements upon adoption.

XML 18 R9.htm IDEA: XBRL DOCUMENT

LIQUIDITY	6 Months Ended
LIQUIDITY	Dec. 31, 2020
LIQUIDITY
LIQUIDITY	NOTE 2 — LIQUIDITY The Company is in the clinical stage and has not yet generated any revenues. For the fiscal year ended June 30, 2020, the Company incurred a net loss of $20.3 million and net cash used in operating activities amounted to $24.2 million. For the six months ended December 31, 2020, the Company incurred a net loss of $10.7 million and net cash used in operating activities amounted to $9.8 million. As of December 31, 2020, the Company had an accumulated deficit of $158.0 million, cash and cash equivalents of $37.6 million and total liabilities of $3.0 million. As discussed in Note 5, on October 9, 2020 the Company received aggregate gross proceeds of $41.0 million from investors in a private placement from the issuance of units that consisted of approximately 2.5 million shares of Common Stock and warrants for the purchase of approximately 0.8 million shares of Common Stock. As discussed in Note 7, COVID-19 has resulted in an economic environment that is unfavorable for many businesses to conduct operations and pursue new debt and equity financings. The U.S. economy has been adversely affected by mass quarantines and government mandated stay-in-place orders to halt the spread of the virus. These orders are frequently changing and contain inherent uncertainty relative to their future application, creating considerable uncertainty surrounding the recovery period for the U.S. economy. The long-term effects on the Company are expected to result in higher costs in order to comply with safeguards to protect patients and staff engaged in clinical activities, and extended periods of time may be required to complete clinical trials. The current economic environment and financial market volatility is expected to make it more challenging for the Company to obtain funding for its clinical programs in the future. Even if an economic recovery occurs faster and more robustly than currently expected, there are no assurances that the Company will be able to obtain equity and debt financings that will be necessary to fund ongoing operations after March 31, 2022. In addition, even if these financing sources are available, they may be on terms that are not acceptable to the Company’s Board of Directors and stockholders. Management believes the Company's existing cash and cash equivalents balance will be adequate to carry out currently planned activities at least through March 31, 2022.

XML 19 R10.htm IDEA: XBRL DOCUMENT

OPERATING LEASES

6 Months Ended

Dec. 31, 2020

OPERATING LEASES

OPERATING LEASES

NOTE 3 — OPERATING LEASES

The carrying value of right-of-use (“ROU”) assets and operating lease liabilities are as follows (in thousands):


	December 31,		June 30,
	2020		2020
Right-of-Use Assets, net	$	547	$	383

Operating Lease Liabilities:
Current	$	316	$	245
Long-term		281		165
Total	$	597	$	410

As of December 31, 2020, the weighted average remaining lease term under operating leases was 2.2 years, and the weighted average discount rate for operating lease liabilities was 7.8%. For the three and six months ended December 31, 2020 , cash paid for amounts included in the measurement of operating lease liabilities was $65,000 and $134,000, respectively. For the three and six months ended December 31, 2019, cash paid for amounts included in the measurement of operating lease liabilities amounted was $68,000 and $136,000, respectively. These cash payments were included in the determination of net cash used in operating activities in the condensed consolidated statements of cash flows.

Future payments under all operating lease agreements as of December 31, 2020 are as follows (in thousands):


Fiscal year ending June 30,
Remainder of fiscal year 2021	$	164
2022		283
2023		117
Thereafter		79
Total lease payments		643
Less imputed interest		(46)
Present value of operating lease liabilities	$	597

XML 20 R11.htm IDEA: XBRL DOCUMENT

LICENSE AGREEMENTS	6 Months Ended
LICENSE AGREEMENTS	Dec. 31, 2020
LICENSE AGREEMENTS
LICENSE AGREEMENTS	NOTE 4 — LICENSE AGREEMENTS Xoma License Agreement In December 2017, the Company entered into a license agreement (“License Agreement”) with XOMA Corporation (“Xoma”), through its wholly-owned subsidiary, XOMA (US) LLC, pursuant to which Xoma granted an exclusive global license to the Company to develop and commercialize Xoma 358 (formerly X358, now RZ358) for all indications. In January 2019, the License Agreement was amended. with an updated payment schedule, as well as revising the amount the Company was required to expend on development of RZ358 and related licensed products, and revised provisions with respect to the Company’s diligence efforts in conducting clinical studies. On March 31, 2020, the parties entered into Amendment No. 3 to the License Agreement to extend the payment schedule for the remaining balance of approximately $2.6 million. The revised payment schedule provided for seven quarterly payments to be paid from March 31, 2020 through September 30, 2021. As discussed in Note 5, the Company completed a private placement of equity securities for gross proceeds of $41.0 million in October 2020, which resulted in acceleration of the entire obligation. On October 23, 2020, the Company paid the outstanding balance of $1.4 million. As of December 31, 2020, the Company does not have any remaining balance payable under Amendment No. 3 to the License Agreement. Upon the achievement of certain clinical and regulatory events, the Company will be required to make up to $37.0 million in aggregate milestone payments to Xoma. In addition to the License Agreement between the Company and Xoma in December 2017, both parties also entered into a stock purchase agreement (“Stock Purchase Agreement”). As of December 31, 2020, Xoma owns approximately 162,000 shares of the Company’s Common Stock. The Stock Purchase Agreement provided Xoma with the right and option to require the Company to use its best efforts to facilitate orderly sales of the shares to a third party or purchase the shares (the “Put Option”). Xoma was permitted to exercise the Put Option for up to a total of 50,000 shares of Common Stock for the calendar year ending December 31, 2020, and up to an additional 50,000 shares thereafter. On November 3, 2020, the Company’s shares of Common Stock were approved for listing on the Nasdaq Capital Market and the Put Option terminated pursuant to the terms of the Stock Purchase Agreement. ActiveSite License Agreement On August 4, 2017, the Company entered into a Development and License Agreement with ActiveSite Pharmaceuticals, Inc. (“ActiveSite”) pursuant to which the Company acquired the rights to ActiveSite’s Plasma Kallikrein Inhibitor program (“PKI Portfolio”). The Company is initially using the PKI Portfolio to develop an oral PKI therapeutic for diabetic macular edema (RZ402) and may use the PKI Portfolio to develop other therapeutics for different indications. The ActiveSite Development and License Agreement requires various milestone payments up to $46.5 million. The first milestone payment for $1.0 million was due after acceptance of an Initial Drug Application, or IND, filed with the U.S. Food and Drug Administration (“FDA”). The Company is also required to pay royalties equal to 2.0% of any sales of products that use the PKI Portfolio. On October 28, 2020, the Company submitted an IND to the FDA. On December 3, 2020, the Company received FDA clearance for the IND application filed by the Company. This clearance resulted in the Company owing the first milestone payment of $1.0 million, which was paid in December 2020. There have been no events that would result in any royalty payments owed under the ActiveSite Development and License Agreement to date.

XML 21 R12.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY

6 Months Ended

Dec. 31, 2020

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY

NOTE 5 — STOCKHOLDERS’ EQUITY


				Additional				Total
	Common Stock			Paid-in		Accumulated		Stockholders’
	Shares	Amount		Capital		Deficit		Equity
Three Months Ended December 31, 2020:
Balances as of September 30, 2020	5,867	$	6	$	155,232	$	(150,856)	$	4,382
Stock-based compensation	—		—		1,141		—		1,141
Fair value of warrants issued to consultants for services	—		—		3		—		3
Issuance of Units for cash	2,485		2		40,998		—		41,000
Advisory fees and other offering costs	—		—		(3,550)		—		(3,550)
Issuance of common stock for services	—		—		7		—		7
Net loss	—		—		—		(7,097)		(7,097)
Balances as of December 31, 2020	8,352	$	8	$	193,831	$	(157,953)	$	35,886


Three Months Ended December 31, 2019:
Balances as of September 30, 2019	5,867	$	6	$	152,595	$	(131,983)	$	20,618
Stock-based compensation	—		—		665		—		665
Fair value of warrants issued to consultants for services	—		—		71		—		71
Net loss	—		—		—		(6,666)		(6,666)
Balances as of December 31, 2019	5,867	$	6	$	153,331	$	(138,649)	$	14,688

Equity Distribution Agreement

On December 18, 2020, the Company and Oppenheimer & Co. Inc. (the “Agent”) entered into an Equity Distribution Agreement (the “EDA”) that provides for an “at the market offering” for the sale of up to $50.0 million in shares of the Company’s Common Stock (the “Placement Shares”) through the Agent. The Agent is acting as sales agent and is required to use commercially reasonable efforts to sell all of the Placement Shares requested to be sold by the Company, consistent with the Agent's normal trading and sales practices, on mutually agreed terms between the Agent and the Company. The EDA will terminate when all of the Placement Shares have been sold, or earlier upon the election of either the Company or the Agent.

Reverse Stock Split

Fiscal 2021 Financing

Fiscal 2020 Private Placement

Restricted Cash

XML 22 R13.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND WARRANTS

6 Months Ended

Dec. 31, 2020

STOCK-BASED COMPENSATION AND WARRANTS

STOCK-BASED COMPENSATION AND WARRANTS

NOTE 6 — STOCK-BASED COMPENSATION AND WARRANTS

Stock Option Plans

The Company currently has two active stock option plans consisting of the 2016 Non-Qualified Stock Option Plan, as amended (the “2016 Plan”), and the 2019 Non Qualified Stock Option Plan (the “2019 Plan”). On July 31, 2019, the 2019 Plan was adopted by the Board of Directors and provides authority to grant non-qualified stock options for up to 300,000 shares of the Company’s Common Stock. The Company also has stock options outstanding to purchase up to approximately 43,000 shares of Common Stock under the 2014 Stock and Incentive Plan (the “2014 Plan”) that terminated on March 21, 2019 and approximately 88,000 shares of Common Stock under the 2015 Stock and Incentive Plan (the "2015 Plan") that terminated on February 23, 2020. Stock options outstanding under the 2014 Plan and the 2015 Plan expire pursuant to their contractual provisions on various dates through 2029. Presented below is a summary as of December 31, 2020 of the number of shares authorized, outstanding, and available for future grants under each of the Company’s stock option plans (in thousands):


	Termination	Number of Shares
Description	Date	Authorized	Outstanding	Available
2014 Plan	March 2019	43	43	—
2015 Plan	February 2020	88	88	—
2016 Plan	October 2021	560	517	43
2019 Plan	July 2029	300	300	—
Total		991	948	43

Stock Options Outstanding


	Shares	Price (1)		Term (2)

Outstanding, July 1, 2020	963	$	33.06	8.1
Stock options granted:
Awards with time-based vesting	8		24.05	9.8
Stock options forfeited:
Awards with time-based vesting	(18)		14.50
Awards with hybrid vesting conditions	(5)		14.50
Outstanding, December 31, 2020	948		33.43	7.5
Vested, December 31, 2020	514		48.56	6.7

⁽¹⁾

Represents the weighted average exercise price.

⁽²⁾

Represents the weighted average remaining contractual term for the number of years until the stock options expire.


	Three Months Ended				Six Months Ended
	December 31,				December 31,
	2020		2019		2020		2019

Research and development	$	493	$	351	$	814	$	925
General and administrative		648		314		961		1,134
Total	$	1,141	$	665	$	1,775	$	2,059

Warrants


	Shares		Price(1)		Term(2)
Outstanding, July 1, 2020	618		$	57.46	2.3
Warrants issued	820	(3)		19.50
Outstanding, December 31, 2020	1,438			35.82	4.6

⁽¹⁾

Represents the weighted average exercise price.

⁽²⁾

Represents the weighted average remaining contractual term for the number of years until the warrants expire.

⁽³⁾

XML 23 R14.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES	6 Months Ended
COMMITMENTS AND CONTINGENCIES	Dec. 31, 2020
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	NOTE 7 — COMMITMENTS AND CONTINGENCIES Commitments Please refer to Note 4 for further discussion of commitments to make milestone payments and to pay royalties under license agreements with Xoma and ActiveSite. COVID-19 In December 2019, COVID-19 was reported to have surfaced in Wuhan, China, and by March 2020 the spread of the virus had resulted in a world-wide pandemic. The U.S. economy has been adversely affected by mass quarantines and government mandated stay-in-place orders to halt the spread of the virus. While these orders are being lifted gradually, a full recovery of the U.S. economy may not occur until 2021 or later. Federal and state governments in the U.S. have approved funding for many programs that may provide financial assistance to individuals and businesses. The Company intends to pursue all material types of government assistance that it may be entitled to. However, no assurance can be provided that the Company will qualify and realize any material benefits from such assistance. COVID-19 has resulted in an economic environment that is unfavorable for many businesses to pursue new equity financings. Accordingly, the current economic environment is expected to present greater challenges for the Company to obtain additional funding for its clinical programs on terms that are acceptable to the Company’s Board of Directors. In February 2020, Rezolute announced the initiation of its Phase 2b trial in congenital hyperinsulinism . New site initiation and enrollment resumed in the quarter ended December 31, 2020. However, similar to many other clinical studies conducted by other companies throughout the world, effects of the pandemic remain uncertain, and no guarantees can be made that hold in future site initiation or enrollment will not be encountered again. There are no mitigation strategies we can employ to help avoid potential timeline delays should there be an extended enrollment pause due to COVID-19. The long-term effects of COVID-19 are expected to require additional safeguards to protect patients and staff engaged in clinical activities, and extended periods of time required to complete clinical trials, both of which are expected to result in higher overall costs. While the current business disruption is expected to be temporary, the long-term financial impact and the duration cannot be reasonably estimated at this time. Legal Matters From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of December 31, 2020, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the Company’s results of operations. At each reporting period, the Company evaluates known claims to determine whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal fees are expensed as incurred.

XML 24 R15.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS	6 Months Ended
RELATED PARTY TRANSACTIONS	Dec. 31, 2020
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	NOTE 8 — RELATED PARTY TRANSACTIONS Related Party Licensing Agreement On September 15, 2020, the Company entered into an exclusive license agreement with Handok, Inc. (the “Handok License”) for the territory of the Republic of Korea. The Handok License relates to pharmaceutical products in final dosage form containing the pharmaceutical compounds developed or to be developed by the Company, including those related to RZ358 and RZ402. The Handok License is in effect for a period of 20 years after the first commercial sale of each product, and requires (i) milestone payments of $0.5 million upon approval of a New Drug Application (“NDA”) for each product in the territory, and (ii) the Company will sell products ordered by Handok at a transfer price equal to 70% of the net selling price of the products. To date, no milestone payments have been earned by the Company. Equity Issuances As discussed in Note 5, on July 23, 2019 Handok, Inc. and Genexine, Inc. agreed to purchase an aggregate of approximately 1.4 million shares of Common Stock at an issuance price of $14.50 per share for gross proceeds of $20.0 million. This purchase was made pursuant to the terms of call options that was issued in connection with an equity offering in January 2019 that resulted in gross proceeds of $25.0 million. On June 26,2020, Handok entered into a 10b5-1 purchasing plan (the "10b5-1 Plan") with JMP Securities. Subject to the terms of the 10b5-1 Plan, Handok has purchased on the open market an aggregate of approximately 189,000 shares of our Common Stock through December 31, 2020. As of December 31, 2020, Handok, Inc. owns approximately 24% and Genexine, Inc. owns approximately 22% of the Company’s outstanding shares of Common Stock. Master Services Agreement Effective July 1, 2019, the Company entered into a Master Services Agreement (“MSA”) with H&G whereby the Company agreed to assist H&G in an evaluation of their long acting growth hormone program referred to as GX-H9. For the six months ended December 31, 2019, the Company charged H&G for employee services of approximately $103,000 and reimbursable expenses incurred with unrelated parties of approximately $144,000, for a total of approximately $247,000. Amounts charged under the MSA for employee services are reflected as a reduction of research and development compensation costs in the accompanying unaudited condensed consolidated statement of operations for the six months ended December 31, 2019. No related expenses were charged for the three and six months ended December 31, 2020, and for the three months ended December 31, 2019.

XML 25 R16.htm IDEA: XBRL DOCUMENT

INCOME TAXES	6 Months Ended
INCOME TAXES	Dec. 31, 2020
INCOME TAXES
INCOME TAXES	NOTE 9 — INCOME TAXES Income tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date operating results, plus any significant unusual or infrequently occurring items which are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating results for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known or as the tax environment changes. For the three and six months ended December 31, 2020 and 2019, the Company did not record any income tax benefit due to a full valuation allowance on its deferred tax assets. The Company did not have any material changes to its conclusions regarding valuation allowances for deferred income tax assets or uncertain tax positions for the three and six months ended December 31, 2020 and 2019.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 26 R17.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE

6 Months Ended

Dec. 31, 2020

EARNINGS PER SHARE

EARNINGS PER SHARE

NOTE 10 — EARNINGS PER SHARE


	2020	2019
Stock options	948	960
Warrants	1,438	924
Total	2,386	1,884

XML 27 R18.htm IDEA: XBRL DOCUMENT

FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS	6 Months Ended
FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS	Dec. 31, 2020
FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS
FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS	NOTE 11 — FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Fair Value Measurements Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair measurement: Level 1—Quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. Level 2—Other than quoted prices included in Level 1 that are observable for the asset and liability, either directly or indirectly through market corroboration, for substantially the full term of the asset or liability. Level 3—Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any market activity for the asset or liability at the measurement date. Due to the relatively short maturity of the respective instruments, the fair value of cash and cash equivalents, accounts payable and accrued liabilities approximated their carrying values as of December 31, 2020 and June 30, 2020. The Company did not have any assets and liabilities measured at fair value on a recurring basis as of December 31, 2020 and June 30, 2020. The Company’s policy is to recognize asset or liability transfers among Level 1, Level 2 and Level 3 as of the actual date of the events or change in circumstances that caused the transfer. During the three and six months ended December 31, 2020 and 2019, the Company did not have any transfers of its assets or liabilities between levels of the fair value hierarchy. Significant Concentrations Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash and cash equivalents at high-quality financial institutions. For the six months ended December 31, 2020, cash deposits have exceeded the amount of federal insurance provided on such deposits. As of December 31, 2020 and June 30, 2020, the Company had cash and cash equivalents with a single financial institution with an aggregate balance of $37.6 million and $10.0 million, respectively. The Company has never experienced any losses related to its investments in cash and cash equivalents.

XML 28 R19.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Dec. 31, 2020
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Nature of Operations	Nature of Operations Rezolute, Inc. (the “Company”) is a clinical stage biopharmaceutical company incorporated in Delaware in 2010.
Reverse Stock Split	Reverse Stock Split In August 2019, the Company’s Board of Directors approved a reverse stock split that was subject to stockholder approval at a special meeting that was concluded on October 28, 2019. Stockholders approved the proposal whereby the Board of Directors had the ability at any time on or before October 23, 2020 to execute a reverse stock split and set an exchange ratio between 20 and 100 shares of the Company’s outstanding Common Stock, $0.001 par value per share, into one issued and outstanding share of Common Stock, without any change in the par value per share or the number of shares of Common Stock authorized. On October 7, 2020, the Board of Directors approved a fifty shares into one share reverse stock split of the Company’s $0.001 par value Common Stock (the “Reverse Stock Split”), resulting in the filing with the Delaware Secretary of State of a Certificate of Amendment (the “Amendment”) to the Company’s Articles of Incorporation. The Amendment was effective on October 9, 2020. In connection with the Reverse Stock Split, proportionate adjustments were made to increase the per share exercise prices and decrease the number of shares of Common Stock issuable upon exercise of stock options and warrants whereby approximately the same aggregate price is required to be paid for such securities upon exercise as had been payable immediately preceding the Reverse Stock Split. In addition, any fractional shares that would otherwise be issued as a result of the Reverse Stock Split were rounded up to the nearest whole share. All references in the accompanying unaudited condensed consolidated financial statements to the number of shares of Common Stock and per share amounts have been retroactively adjusted to give effect to the Reverse Stock Split.
Basis of Presentation	Basis of Presentation The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the SEC for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The condensed consolidated balance sheet as of June 30, 2020, has been derived from the Company’s audited consolidated financial statements. The unaudited interim financial statements should be read in conjunction with the Company’s 2020 Form 10-K, which contains the Company’s audited financial statements and notes thereto, together with the Management’s Discussion and Analysis of Financial Condition and Results of Operations for the year ended fiscal June 30, 2020. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnote disclosures necessary for a comprehensive presentation of financial position, results of operations, and cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the three and six months ended December 31, 2020 are not necessarily indicative of the financial condition and results of operations that may be expected for any future interim period or for the fiscal year ending June 30, 2021.
Reclassifications	Reclassifications Certain amounts in the previously issued comparative interim financial statements for the three and six months ended December 31, 2019 have been reclassified to conform to the current interim financial statement presentation. These reclassifications had no effect on the previously reported net loss, working capital, cash flows and stockholders’ equity.
Consolidation	Consolidation The Company has three wholly owned subsidiaries consisting of AntriaBio Delaware, Inc., Rezolute (Bio) Ireland Limited, and Rezolute Bio UK, Ltd. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its three wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and the accompanying notes. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company’s significant accounting estimates include, but are not necessarily limited to, fair value of share-based payments, management’s assessment of going concern, accrued clinical trial liabilities, estimates of the probability and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses. Actual results could differ from those estimates.
Risks and Uncertainties	Risks and Uncertainties The Company's operations may be subject to significant risks and uncertainties including financial, operational, regulatory and other risks associated with a clinical stage company, including the potential risk of business failure as discussed further in Note 2, and the future impact of COVID-19 as discussed in Note 7.
Summary of Significant Accounting Policies	Significant Accounting Policies During the six months ended December 31, 2020, there have been no changes in our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Standards Required to be Adopted in Future Years. The following accounting standards are not yet effective; management has not completed its evaluation to determine the impact that adoption of this standard will have on the Company’s consolidated financial statements. In June 2016, the Financial Accounting Standards Board ("FASB”) issued Accounting Standards Update ("ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the guidance on the impairment of financial instruments. This update adds an impairment model (known as the current expected credit losses model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes, as an allowance, its estimate of expected credit losses. In November 2019, ASU 2016-13 was amended by ASU 2019-10, Financial Instruments- Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) whereby the effective date for ASU 2016-13 for smaller reporting companies is now required for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity). ASU 2020-06 reduces the number of accounting models for convertible debt instruments and convertible preferred stock, which results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Additionally, ASU 2020-06 affects the diluted earnings per share calculation for instruments that may be settled in cash or shares and for convertible instruments and requires enhanced disclosures about the terms of convertible instruments and contracts in an entity's own equity. ASU 2020-06 allows entities to use a modified or full retrospective transition method and is effective for smaller reporting companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not currently expected to have a material impact on the Company's financial statements upon adoption.

XML 29 R20.htm IDEA: XBRL DOCUMENT

OPERATING LEASES (Tables)

6 Months Ended

Dec. 31, 2020

OPERATING LEASES

Summary of carrying value of ROU assets and operating lease liabilities

The carrying value of right-of-use (“ROU”) assets and operating lease liabilities are as follows (in thousands):


	December 31,		June 30,
	2020		2020
Right-of-Use Assets, net	$	547	$	383

Operating Lease Liabilities:
Current	$	316	$	245
Long-term		281		165
Total	$	597	$	410

Summary of future payments under operating lease agreements

Future payments under all operating lease agreements as of December 31, 2020 are as follows (in thousands):


Fiscal year ending June 30,
Remainder of fiscal year 2021	$	164
2022		283
2023		117
Thereafter		79
Total lease payments		643
Less imputed interest		(46)
Present value of operating lease liabilities	$	597

XML 30 R21.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Tables)

6 Months Ended

Dec. 31, 2020

STOCKHOLDERS' EQUITY

Summary of changes in stockholder's equity


				Additional				Total
	Common Stock			Paid-in		Accumulated		Stockholders’
	Shares	Amount		Capital		Deficit		Equity
Three Months Ended December 31, 2020:
Balances as of September 30, 2020	5,867	$	6	$	155,232	$	(150,856)	$	4,382
Stock-based compensation	—		—		1,141		—		1,141
Fair value of warrants issued to consultants for services	—		—		3		—		3
Issuance of Units for cash	2,485		2		40,998		—		41,000
Advisory fees and other offering costs	—		—		(3,550)		—		(3,550)
Issuance of common stock for services	—		—		7		—		7
Net loss	—		—		—		(7,097)		(7,097)
Balances as of December 31, 2020	8,352	$	8	$	193,831	$	(157,953)	$	35,886


Three Months Ended December 31, 2019:
Balances as of September 30, 2019	5,867	$	6	$	152,595	$	(131,983)	$	20,618
Stock-based compensation	—		—		665		—		665
Fair value of warrants issued to consultants for services	—		—		71		—		71
Net loss	—		—		—		(6,666)		(6,666)
Balances as of December 31, 2019	5,867	$	6	$	153,331	$	(138,649)	$	14,688

XML 31 R22.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND WARRANTS (Tables)

6 Months Ended

Dec. 31, 2020

STOCK-BASED COMPENSATION AND WARRANTS

Schedule of the number of shares authorized, outstanding, and available for future grants under stock option

Presented below is a summary as of December 31, 2020 of the number of shares authorized, outstanding, and available for future grants under each of the Company’s stock option plans (in thousands):


	Termination	Number of Shares
Description	Date	Authorized	Outstanding	Available
2014 Plan	March 2019	43	43	—
2015 Plan	February 2020	88	88	—
2016 Plan	October 2021	560	517	43
2019 Plan	July 2029	300	300	—
Total		991	948	43

Summary of the stock option activity


	Shares	Price (1)		Term (2)

Outstanding, July 1, 2020	963	$	33.06	8.1
Stock options granted:
Awards with time-based vesting	8		24.05	9.8
Stock options forfeited:
Awards with time-based vesting	(18)		14.50
Awards with hybrid vesting conditions	(5)		14.50
Outstanding, December 31, 2020	948		33.43	7.5
Vested, December 31, 2020	514		48.56	6.7

⁽¹⁾

Represents the weighted average exercise price.

⁽²⁾

Represents the weighted average remaining contractual term for the number of years until the stock options expire.

Schedule of stock-based compensation expense


	Three Months Ended				Six Months Ended
	December 31,				December 31,
	2020		2019		2020		2019

Research and development	$	493	$	351	$	814	$	925
General and administrative		648		314		961		1,134
Total	$	1,141	$	665	$	1,775	$	2,059

Schedule of warrant activity


	Shares		Price(1)		Term(2)
Outstanding, July 1, 2020	618		$	57.46	2.3
Warrants issued	820	(3)		19.50
Outstanding, December 31, 2020	1,438			35.82	4.6

⁽¹⁾

Represents the weighted average exercise price.

⁽²⁾

Represents the weighted average remaining contractual term for the number of years until the warrants expire.

XML 32 R23.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE (Tables)

6 Months Ended

Dec. 31, 2020

EARNINGS PER SHARE

Summary of potential common stock equivalents were excluded from the computation of diluted net loss per share

As of December 31, 2020 and 2019, the following outstanding potential common stock equivalents were excluded from the computation of diluted net loss per share since the impact of inclusion was anti-dilutive (in thousands):


	2020	2019
Stock options	948	960
Warrants	1,438	924
Total	2,386	1,884

XML 33 R24.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impact of adoption (Details)			6 Months Ended
	Oct. 23, 2020	Oct. 07, 2020 $ / shares	Dec. 31, 2020 item $ / shares	Jun. 30, 2020 $ / shares	Aug. 31, 2019 $ / shares
Nature of operations and Significant accounting policies
Reverse stock split, Exchange ratio		0.02
Common Stock, Par or Stated Value Per Share \| $ / shares		$ 0.001	$ 0.001	$ 0.001	$ 0.001
Number of wholly owned subsidiaries \| item			3
Minimum
Nature of operations and Significant accounting policies
Reverse stock split, Exchange ratio	50
Maximum
Nature of operations and Significant accounting policies
Reverse stock split, Exchange ratio	1

XML 34 R25.htm IDEA: XBRL DOCUMENT

LIQUIDITY (Details) - USD ($) $ in Thousands, shares in Millions		3 Months Ended		6 Months Ended		12 Months Ended
	Oct. 09, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
LIQUIDITY
Net loss		$ (7,097)	$ (6,666)	$ (10,717)	$ (11,746)	$ 20,300
Net cash used in operating activities				(9,814)	(14,411)	24,200
Accumulated deficit		(157,953)		(157,953)		(147,236)
Cash, cash equivalents and restricted cash		37,600	$ 19,712	37,600	$ 19,712	9,955	$ 11,573
Total liabilities		$ 3,016		$ 3,016		$ 3,600
Gross proceeds from private placement of equity shares	$ 41,000
Number of shares issued	2.5
Warrants for the purchase of shares of Common Stock	$ 800

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

XML 35 R26.htm IDEA: XBRL DOCUMENT

OPERATING LEASES - Additional Information (Details)		3 Months Ended		6 Months Ended
OPERATING LEASES - Additional Information (Details)	Oct. 28, 2020 USD ($) ft²	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Jun. 30, 2020 USD ($)
OPERATING LEASES
Cash paid for amounts included in measurement of operating lease liabilities		$ 65,000	$ 68,000	$ 134,000	$ 136,000
Lease space \| ft²	5,000
Average monthly rent				139,000	$ 136,000
Lease and rental expense	$ 8,700
Option to extend the lease	false
Discount rate	6.00%
Renewal term	40 months
Right-of-use assets, net	$ 300,000	547,000		547,000		$ 383,000
Operating lease liability	$ 300,000	$ 597,000		$ 597,000		$ 410,000

XML 36 R27.htm IDEA: XBRL DOCUMENT

OPERATING LEASES - Assets and operating lease liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Oct. 28, 2020	Jun. 30, 2020
Carrying value of ROU assets and operating lease liabilities
Right-of-use assets, net	$ 547	$ 300	$ 383
Operating Lease Liabilities:
Current	316		245
Long-term	281		165
Total	$ 597	$ 300	$ 410
Operating lease weighted average remaining lease term1	2 years 2 months 12 days
Weighted average discount rate	7.80%

XML 37 R28.htm IDEA: XBRL DOCUMENT

OPERATING LEASES - Operating lease agreements (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Oct. 28, 2020	Jun. 30, 2020
Future lease payments related to operating lease agreements
Remainder of fiscal year 2021	$ 164
2022	283
2023	117
Thereafter	79
Total lease payments	643
Less imputed interest	(46)
Present value of operating lease liabilities	$ 597	$ 300	$ 410

XML 38 R29.htm IDEA: XBRL DOCUMENT

LICENSE AGREEMENTS - Remaining payment obligations (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Jun. 30, 2020
LICENSE AGREEMENTS
Less long term portion of payable	$ 0	$ (209)
Current portion of payable	$ 0	$ 1,600

XML 39 R30.htm IDEA: XBRL DOCUMENT

LICENSE AGREEMENTS - Additional Information - (Detail) - USD ($) $ in Thousands			1 Months Ended			3 Months Ended	6 Months Ended
	Oct. 23, 2020	Oct. 09, 2020	Dec. 31, 2020	Oct. 31, 2020	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Proceeds from private placement of equity shares		$ 41,000
Stock Issued During Period, Value, Issued for Services						$ 7	$ 7
License agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock Issued During Period, Value, Issued for Services					$ 2,600
Activesite Pharmaceuticals Inc
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone Payments			$ 1,000
Maximum Amount of Milestone Events							46,500
First milestone payment due after completion of the preclinical work			$ 1,000			$ 1,000	$ 1,000
Royalties percentage							2.00%
Xoma
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone Payments							$ 37,000
Proceeds from private placement of equity shares				$ 41,000
Payments of outstanding balance of license	$ 1,400
Xoma \| License agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock Issued During Period, Shares, Other							162,000
Put Option [Member] \| Xoma \| License agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Description Of Option Indexed To Issuers Equity Shares							Xoma was permitted to exercise the Put Option for up to a total of 50,000 shares of Common Stock for the calendar year ending December 31, 2020, and up to an additional 50,000 shares thereafter.

XML 40 R31.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY - (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended		12 Months Ended
STOCKHOLDERS' EQUITY - (Details) - USD ($) $ in Thousands	Oct. 09, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2020
Increase (Decrease) in Stockholders' Equity
Balance		$ 4,382	$ 20,618	$ 7,365	$ 1,752	$ 1,752
Stock-based compensation		1,141	665	1,775	2,059
Fair value of warrants issued to consultants for services		3	71	6	73
Issuance of Units for cash		41,000		41,000
Issuance of Units for cash (In shares)	2,500,000
Advisory fees and other offering costs		(3,550)		(3,550)	(1,500)
Issuance of common stock for services		7		7
Net loss		(7,097)	(6,666)	(10,717)	(11,746)	20,300
Balance		35,886	14,688	35,886	14,688	7,365
Common Stock
Increase (Decrease) in Stockholders' Equity
Balance		$ 6	$ 6	$ 6	$ 4	$ 4
Balance (in shares)		5,867	5,867	5,867	4,208	4,208
Issuance of Units for cash		$ 2		$ 2
Issuance of Units for cash (In shares)		2,485		2,485
Balance		$ 8	$ 6	$ 8	$ 6	$ 6
Balance (in shares)		8,352	5,867	8,352	5,867	5,867
Additional Paid-in Capital
Increase (Decrease) in Stockholders' Equity
Balance		$ 155,232	$ 152,595	$ 154,595	$ 128,651	$ 128,651
Stock-based compensation		1,141	665	1,775	2,059
Fair value of warrants issued to consultants for services		3	71	6	73
Issuance of Units for cash		40,998		40,998
Advisory fees and other offering costs		(3,550)		(3,550)	(1,500)
Issuance of common stock for services		7		7
Net loss		0	0	0	0
Balance		193,831	153,331	193,831	153,331	154,595
Accumulated Deficit
Increase (Decrease) in Stockholders' Equity
Balance		(150,856)	(131,983)	(147,236)	(126,903)	(126,903)
Stock-based compensation		0	0	0	0
Fair value of warrants issued to consultants for services		0	0	0	0
Issuance of Units for cash		0		0
Advisory fees and other offering costs		0		0	0
Issuance of common stock for services		0		0
Net loss		(7,097)	(6,666)	(10,717)	(11,746)
Balance		$ (157,953)	$ (138,649)	$ (157,953)	$ (138,649)	$ (147,236)

XML 41 R32.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY - Additional Information (Details) $ / shares in Units, $ in Thousands							1 Months Ended	2 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 18, 2020 USD ($)	Oct. 09, 2020 $ / shares shares	Sep. 16, 2020	Jul. 23, 2019 USD ($) $ / shares shares	Jun. 19, 2019 USD ($)	Jul. 23, 2019 $ / shares shares	Aug. 31, 2019 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares	Dec. 31, 2019 USD ($)	Dec. 31, 2020 USD ($) $ / shares	Dec. 31, 2019 USD ($)	Jun. 30, 2020 USD ($) $ / shares shares
Class of Stock [Line Items]
Agents Commission (In percent)											0.00%
Deferred offering cost	$ 122								$ 122		$ 122		$ 0
Warrant price (per share) \| $ / shares	$ 35.82								$ 35.82		$ 35.82		$ 57.46
Qualified expenditures										$ 1,600		$ 2,300
Stock Issued During Period, Shares, New Issues \| shares			2,500,000
Stock Issued During Period, Value, New Issues									$ 41,000		$ 41,000
Share Price \| $ / shares	$ 14.50								$ 14.50		$ 14.50
Volume weighted average closing price of common stock											75.00%
Gross proceeds from issuance of common stock											$ 41,000	0
Purchase of Common Stock											10,000
Restricted cash										1,500		$ 1,500
Accumulated Deficit
Class of Stock [Line Items]
Stock Issued During Period, Value, New Issues									$ 0		0
Other Investors [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues \| shares								279,000
Share Price \| $ / shares								$ 14.50
Gross proceeds from issuance of common stock								$ 4,100
Other Investors [Member] \| Maximum
Class of Stock [Line Items]
Stock Issued During Period, Value, New Issues						$ 10,000
Investor [Member]
Class of Stock [Line Items]
Additional Transaction fees (In percent)				6.00%
Sale of units \| shares			2,500,000
Warrants holders entitle to purchase common stock \| shares			800,000
Warrant price (per share) \| $ / shares			$ 19.50
Professional fees and offering costs											$ 1,100
Reverse stock split ratio	0.02								0.02		0.02
Stock Issued During Period, Shares, New Issues \| shares	189,000				1,400,000		1,400,000
Stock Issued During Period, Value, New Issues						$ 20,000
Proceeds from Stock Options Exercised					$ 14,500
Share Price \| $ / shares	$ 16.50				$ 14.50		$ 14.50		$ 16.50		$ 16.50
Gross proceeds from issuance of common stock					$ 20,000						$ 41,000
Amount of advisory fee payable	$ 2,500							$ 1,500	$ 2,500		2,500
Net proceeds from private placement											37,500
Percent of advisory fee payable				6.00%				6.00%
EDA [Member]
Class of Stock [Line Items]
Agents Commission (In percent)		3.00%
Deferred offering cost	$ 100								$ 100		$ 100
Stock Issued During Period, Value, New Issues		$ 50,000
Private Placement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues \| shares													262,000
Gross proceeds from issuance of common stock													$ 3,800
Private Placement [Member] \| Investor [Member]
Class of Stock [Line Items]
Net proceeds from private placement										$ 22,600

XML 42 R33.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND WARRANTS - Stock option plans (Details) - shares shares in Thousands	Dec. 31, 2020	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	991
Number of shares outstanding	948	963
Number of shares available	43
2014 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	43
Number of shares outstanding	43
2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	88
Number of shares outstanding	88
2016 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	560
Number of shares outstanding	517
Number of shares available	43
2019 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	300
Number of shares outstanding	300

XML 43 R34.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND WARRANTS - Stock options outstanding (Details) - $ / shares shares in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Jun. 30, 2020
Number of Options
Outstanding	963
Outstanding	948	963
Vested	514
Weighted Average Exercise Price
Outstanding	$ 33.06
Warrants issued( In years)	19.50
Outstanding	33.43	$ 33.06
Vested	$ 48.56
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Lives	7 years 6 months	8 years 1 month 6 days
Vested	6 years 8 months 12 days
Award with time-based vesting
Number of Options
Shares granted	8
Forfeited	(18)
Weighted Average Exercise Price
Warrants issued( In years)	$ 24.05
Forfeited	$ 14.50
Weighted Average Remaining Contractual Life
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term	9 years 9 months 18 days
Awards with hybrid vesting conditions
Number of Options
Forfeited	(5)
Weighted Average Exercise Price
Forfeited	$ 14.50

XML 44 R35.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND WARRANTS - Stock based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 1,141	$ 665	$ 1,775	$ 2,059
Research and Development Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	493	351	814	925
General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 648	$ 314	$ 961	$ 1,134

XML 45 R36.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND WARRANTS - Warrants (Details) - $ / shares shares in Thousands	6 Months Ended
	Dec. 31, 2020	Jun. 30, 2020
STOCK-BASED COMPENSATION AND WARRANTS
Warrants outstanding-Beginning (In shares)	618
Weighted average exercise price( Per share)	$ 57.46
Weighted average remaining contractual term	4 years 7 months 6 days	2 years 3 months 18 days
Warrants issued (In shares)	820
Warrants issued( In years)	$ 19.50
Warrants outstanding-Ending (In shares)	1,438
Weighted average exercise price (Per share)	$ 35.82

XML 46 R37.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND WARRANTS - Additional information (Details) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended			6 Months Ended
	Jul. 31, 2019 item $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Sep. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2020 USD ($) $ / shares shares	Dec. 31, 2019 USD ($)	Nov. 02, 2020 USD ($)	Jun. 30, 2020 $ / shares shares	Feb. 23, 2020 shares	Mar. 21, 2019 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		991,000			991,000
Weighted average exercise price( Per share) \| $ / shares		$ 35.82			$ 35.82			$ 57.46
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, stock options \| $		$ 2,200			$ 2,200
Compensation cost \| $		$ 1,141		$ 665	$ 1,775	$ 2,059
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition					1 year 8 months 12 days
Class of Warrant or Right, Outstanding		1,438,000			1,438,000			618,000
Hybrid Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, stock options \| $							$ 1,900
2014 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options outstanding terminated										43,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		43,000			43,000
2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options outstanding terminated									88,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		88,000			88,000
Employees and Directors \| Non Qualified Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	300,000
Employee stock options \| Hybrid Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	200,000
Vesting period	36 months
Period for which recipient has been employed by the entity	1 year
Minimal Stock Price For Vesting \| $ / shares	$ 29.00
Threshold trading days for minimal stock price for vesting \| item	20
Threshold consecutive trading days for minimal stock price for vesting \| item	30
Employee stock options \| Unrecognized compensation cost recognized through December 2020 \| Hybrid Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost \| $			$ 500
Employee stock options \| Unrecognized compensation cost recognized through July 2024 \| Hybrid Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, stock options \| $			$ 1,400
Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued (years)					7 years

XML 47 R38.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details) - USD ($)					1 Months Ended		3 Months Ended		6 Months Ended
RELATED PARTY TRANSACTIONS (Details) - USD ($)	Dec. 31, 2020	Oct. 09, 2020	Sep. 15, 2020	Jul. 23, 2019	Jul. 23, 2019	Jan. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Number of shares issued		2,500,000
Price per share	$ 14.50						$ 14.50		$ 14.50
Gross proceeds from issuance						$ 25,000,000
Fair Value Adjustment of Warrants									$ 6,000	$ 73,000
Related Party Transaction, Employee Services							$ 0	$ 0	$ 0	0
Master Services Agreement ("MSA")
Related Party Transaction [Line Items]
Fair Value Adjustment of Warrants										$ 103,000
Related Party Licensing Agreement
Related Party Transaction [Line Items]
Pharmaceutical License Agreement, Term			20 years
Pharmaceutical License Agreement, Milestone Payment			$ 500,000
Pharmaceutical License Agreement, Transfer Price			70.00%
Milestone payments earned			$ 0
Investor [Member]
Related Party Transaction [Line Items]
Number of shares issued	189,000			1,400,000	1,400,000
Price per share	$ 16.50			$ 14.50	$ 14.50		$ 16.50		$ 16.50
Gross proceeds from issuance				$ 20,000,000
Investor [Member] \| Master Services Agreement ("MSA")
Related Party Transaction [Line Items]
Investor relation expenses									$ 144,000
General and administrative expenses									$ 247,000
Handok [Member]
Related Party Transaction [Line Items]
Ownership interest by related party	24.00%						24.00%		24.00%
Genexine [Member]
Related Party Transaction [Line Items]
Ownership interest by related party	22.00%						22.00%		22.00%

XML 48 R39.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE - Anti-dilutive (Details) - shares shares in Thousands	3 Months Ended	6 Months Ended
	Dec. 31, 2019	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents were excluded from the computation of diluted net loss per share	1,884	2,386
Employee stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents were excluded from the computation of diluted net loss per share	960	948
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents were excluded from the computation of diluted net loss per share	924	1,438

XML 49 R40.htm IDEA: XBRL DOCUMENT

FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS
Cash, cash equivalents, and restricted cash	$ 37,600	$ 9,955	$ 19,712	$ 11,573

EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 51 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 109 293 1 false 34 0 false 6 false false R1.htm 00090 - Document - Document And Entity Information Sheet http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 00100 - Statement - Unaudited Condensed Consolidated Balance Sheets Sheet http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets Unaudited Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.rezolutebio.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical Unaudited Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.rezolutebio.com/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.rezolutebio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 00305 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://www.rezolutebio.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 6 false false R7.htm 00400 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.rezolutebio.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 10101 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPolicies NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 10201 - Disclosure - LIQUIDITY Sheet http://www.rezolutebio.com/role/DisclosureLiquidity LIQUIDITY Notes 9 false false R10.htm 10301 - Disclosure - OPERATING LEASES Sheet http://www.rezolutebio.com/role/DisclosureOperatingLeases OPERATING LEASES Notes 10 false false R11.htm 10401 - Disclosure - LICENSE AGREEMENTS Sheet http://www.rezolutebio.com/role/DisclosureLicenseAgreements LICENSE AGREEMENTS Notes 11 false false R12.htm 10501 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.rezolutebio.com/role/DisclosureStockholdersEquity STOCKHOLDERS' EQUITY Notes 12 false false R13.htm 10601 - Disclosure - STOCK-BASED COMPENSATION AND WARRANTS Sheet http://www.rezolutebio.com/role/DisclosureStockBasedCompensationAndWarrants STOCK-BASED COMPENSATION AND WARRANTS Notes 13 false false R14.htm 10701 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 14 false false R15.htm 10801 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 15 false false R16.htm 10901 - Disclosure - INCOME TAXES Sheet http://www.rezolutebio.com/role/DisclosureIncomeTaxes INCOME TAXES Notes 16 false false R17.htm 11001 - Disclosure - EARNINGS PER SHARE Sheet http://www.rezolutebio.com/role/DisclosureEarningsPerShare EARNINGS PER SHARE Notes 17 false false R18.htm 11101 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Sheet http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrations FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Notes 18 false false R19.htm 20102 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 19 false false R20.htm 30303 - Disclosure - OPERATING LEASES (Tables) Sheet http://www.rezolutebio.com/role/DisclosureOperatingLeasesTables OPERATING LEASES (Tables) Tables http://www.rezolutebio.com/role/DisclosureOperatingLeases 20 false false R21.htm 30503 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.rezolutebio.com/role/DisclosureStockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.rezolutebio.com/role/DisclosureStockholdersEquity 21 false false R22.htm 30603 - Disclosure - STOCK-BASED COMPENSATION AND WARRANTS (Tables) Sheet http://www.rezolutebio.com/role/DisclosureStockBasedCompensationAndWarrantsTables STOCK-BASED COMPENSATION AND WARRANTS (Tables) Tables http://www.rezolutebio.com/role/DisclosureStockBasedCompensationAndWarrants 22 false false R23.htm 31003 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://www.rezolutebio.com/role/DisclosureEarningsPerShareTables EARNINGS PER SHARE (Tables) Tables http://www.rezolutebio.com/role/DisclosureEarningsPerShare 23 false false R24.htm 40101 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impact of adoption (Details) Sheet http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesImpactOfAdoptionDetails NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impact of adoption (Details) Details 24 false false R25.htm 40201 - Disclosure - LIQUIDITY (Details) Sheet http://www.rezolutebio.com/role/DisclosureLiquidityDetails LIQUIDITY (Details) Details http://www.rezolutebio.com/role/DisclosureLiquidity 25 false false R26.htm 40301 - Disclosure - OPERATING LEASES - Additional Information (Details) Sheet http://www.rezolutebio.com/role/DisclosureOperatingLeasesAdditionalInformationDetails OPERATING LEASES - Additional Information (Details) Details 26 false false R27.htm 40302 - Disclosure - OPERATING LEASES - Assets and operating lease liabilities (Details) Sheet http://www.rezolutebio.com/role/DisclosureOperatingLeasesAssetsAndOperatingLeaseLiabilitiesDetails OPERATING LEASES - Assets and operating lease liabilities (Details) Details 27 false false R28.htm 40303 - Disclosure - OPERATING LEASES - Operating lease agreements (Details) Sheet http://www.rezolutebio.com/role/DisclosureOperatingLeasesOperatingLeaseAgreementsDetails OPERATING LEASES - Operating lease agreements (Details) Details 28 false false R29.htm 40401 - Disclosure - LICENSE AGREEMENTS - Remaining payment obligations (Details) Sheet http://www.rezolutebio.com/role/DisclosureLicenseAgreementsRemainingPaymentObligationsDetails LICENSE AGREEMENTS - Remaining payment obligations (Details) Details 29 false false R30.htm 40402 - Disclosure - LICENSE AGREEMENTS - Additional Information - (Detail) Sheet http://www.rezolutebio.com/role/DisclosureLicenseAgreementsAdditionalInformationDetail LICENSE AGREEMENTS - Additional Information - (Detail) Details 30 false false R31.htm 40501 - Disclosure - STOCKHOLDERS' EQUITY - (Details) Sheet http://www.rezolutebio.com/role/DisclosureStockholdersEquityDetails STOCKHOLDERS' EQUITY - (Details) Details http://www.rezolutebio.com/role/DisclosureStockholdersEquityTables 31 false false R32.htm 40502 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details) Sheet http://www.rezolutebio.com/role/DisclosureStockholdersEquityAdditionalInformationDetails STOCKHOLDERS' EQUITY - Additional Information (Details) Details 32 false false R33.htm 40601 - Disclosure - STOCK-BASED COMPENSATION AND WARRANTS - Stock option plans (Details) Sheet http://www.rezolutebio.com/role/DisclosureStockBasedCompensationAndWarrantsStockOptionPlansDetails STOCK-BASED COMPENSATION AND WARRANTS - Stock option plans (Details) Details 33 false false R34.htm 40602 - Disclosure - STOCK-BASED COMPENSATION AND WARRANTS - Stock options outstanding (Details) Sheet http://www.rezolutebio.com/role/DisclosureStockBasedCompensationAndWarrantsStockOptionsOutstandingDetails STOCK-BASED COMPENSATION AND WARRANTS - Stock options outstanding (Details) Details 34 false false R35.htm 40603 - Disclosure - STOCK-BASED COMPENSATION AND WARRANTS - Stock based compensation expense (Details) Sheet http://www.rezolutebio.com/role/DisclosureStockBasedCompensationAndWarrantsStockBasedCompensationExpenseDetails STOCK-BASED COMPENSATION AND WARRANTS - Stock based compensation expense (Details) Details 35 false false R36.htm 40604 - Disclosure - STOCK-BASED COMPENSATION AND WARRANTS - Warrants (Details) Sheet http://www.rezolutebio.com/role/DisclosureStockBasedCompensationAndWarrantsWarrantsDetails STOCK-BASED COMPENSATION AND WARRANTS - Warrants (Details) Details 36 false false R37.htm 40605 - Disclosure - STOCK-BASED COMPENSATION AND WARRANTS - Additional information (Details) Sheet http://www.rezolutebio.com/role/DisclosureStockBasedCompensationAndWarrantsAdditionalInformationDetails STOCK-BASED COMPENSATION AND WARRANTS - Additional information (Details) Details 37 false false R38.htm 40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails RELATED PARTY TRANSACTIONS (Details) Details http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactions 38 false false R39.htm 41001 - Disclosure - EARNINGS PER SHARE - Anti-dilutive (Details) Sheet http://www.rezolutebio.com/role/DisclosureEarningsPerShareAntiDilutiveDetails EARNINGS PER SHARE - Anti-dilutive (Details) Details 39 false false R40.htm 41101 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Details) Sheet http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsDetails FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Details) Details http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrations 40 false false All Reports Book All Reports rzlt-20201231.xml rzlt-20201231.xsd rzlt-20201231_cal.xml rzlt-20201231_def.xml rzlt-20201231_lab.xml rzlt-20201231_pre.xml http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true ZIP 55 0001104659-21-019846-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-019846-xbrl.zip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end